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ABSTRACT 
The immune system protects us from infection by pathogens such as viruses and 
bacteria. T cells play a central role in the immune response to fight against pathogens and 
orchestrate other immune cells by producing cytokines or chemokines. An overreactive 
immune response can lead to autoimmune diseases, therefore the immune system must 
possess negative regulation mechanisms. In the periphery, naturally arising regulatory T 
cells (CD4+CD25+Foxp3+ T cells; nTregs) negatively regulate immune responses and 
play an important role in maintaining immune homeostasis by suppressing other immune 
cells. When antigens derived from pathogens are present, conventional CD4+ T cells 
recognize their cognate antigen and proliferate. After pathogen clearance, expanded 
effector T cells eventually decline in number due to activation induced cell death (AICD) 
to terminate immune response. However, it is not understood how nTregs respond to 
antigen stimulation. Since effector T cells are needed for an immune response and nTregs 
are required for maintaining peripheral tolerance, the responses to antigen stimulation in 
nTregs might be different from other CD4+ T cells. 
We previously discovered the phenomenon that nTregs survive and expand when 
stimulated with plate-bound anti-CD3/anti-CD28 antibodies which mimic antigen 
stimulation in the presence of IL-2, while conventional T cells undergo massive 
  xiii 
apoptosis. This suggests that there is a differential survival mechanism between nTregs 
and conventional T cells. Further, we found that T cell stimulation under this stimulation 
was mediated by a novel form of the apoptotic pathway (p53-induced and CD28-
dependent apoptosis; PICA) and distinct from classical AICD.     
In my dissertation, I hypothesized that this differential survival mechanism 
between nTreg and conventional CD4+ T cells against PICA might be important in 
keeping the balance between nTregs and non-Tregs thus maintaining immune 
homeostasis in a physiological environment. Therefore, I investigated by which 
mechanisms nTregs survive under PICA inducing stimuli. I found that at least two 
signaling pathways are altered in nTregs under PICA induced stimulation thus mediating 
cell survival.  
I conducted TCR proximal signaling study and identified that RasGRP1 
expression was substantially reduced and its downstream Ras-Erk pathway was impaired 
in nTregs. nTregs express a transcription factor, Foxp3 which positively or negatively 
regulates the expression of multiple genes related to nTreg functions. I performed a ChIP 
assay to determine if rasgrp1 gene expression is negatively regulated by Foxp3 in 
nTregs, and identified that rasgrp1 gene was indeed a Foxp3 target. Further, loss of 
RasGRP1 expression rendered conventional CD4+ T cells resistant to PICA, suggesting 
that reduced RasGRP1 expression in Tregs is important for cell survival under PICA 
inducing stimuli.  
Upon TCR activation, T cells produce various cytokines such as IL-2. TGF-b is a 
pleiotropic cytokine which is also produced by T cells. Tregs, but not other conventional 
  xiv 
T cells, express a unique form of membrane bound TGF-b upon TCR activation. I 
demonstrated that TGF-b signaling is required for Tregs to survive PICA. Conversely, 
conventional CD4+ T cells became resistant to PICA and underwent robust expansion 
instead of apoptosis, with the reduction of the proapoptotic protein Bim, when an active 
form of exogenous TGF-b is present. These data suggest a novel role for TGF-b in nTreg 
biology and potentially involvement in expansion of effector T cells under PICA 
inducing stimuli. 
        Taken together, my work provides insight into how nTregs survive under antigen 
stimulation while conventional CD4+ T cells undergo apoptosis. My work suggests that 
reduced RasGRP1 expression and TGF-b signaling mediate the survival of nTregs under 
PICA inducing stimuli. These altered signals in Tregs are likely regulating the balance of 
nTreg and conventional T cells during an immune response, thus maintaining immune 
homeostasis. 
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CHAPTER ONE 
LITERATURE REVIEW 
  
CD4+ T CELL IMMUNITY 
 
Introduction 
    The immune system protects us from non-self invasions such as viruses or bacterial 
infections. CD4+ T cells play a major role in orchestrating other immune cells by 
producing cytokines or chemokines during the adaptive immune response, hence they are 
also called helper T cells. For example, CD4+ T cells help B cells to make antibodies and 
also help macrophages to have enhanced activity to fight against pathogens during 
infections.  CD4+ T cells express T cell receptors (TCRs) on their surface and recognize 
peptides derived from pathogens presented on major histocompatibility class II (MHC 
class II) that are expressed by antigen presenting cells (APCs). Engagement of TCRs with 
MHC class II-peptide complex leads to activation of TCR signaling cascades which 
promote transcription of multiple genes including cytokine genes. 
       In 1986, Mossman and Coffman reported that CD4+ T cell lines were divided into 
two distinct populations by cytokine production, IFN-γ producers or IL-4 producers 
(Mosmann et al., 1986; Mosmann and Coffman, 1989). This was the discovery of Th1 
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and Th2 subsets. Heinzel et al. reported that BALB/c mice were more susceptible than 
C57BL/6 mice during Leishmania major infections (Heinzel and Maier, 1999). This is 
because BALB/c mice are biased toward a Th2 response rather than Th1. This promotes a 
humoral response instead of a cellular immune response against intracellular pathogens. 
This finding suggests a correct immune response at the right time leads to elimination of 
pathogens, however dysregulation of differentiation of CD4+ T cells can cause chronic 
infection.  
       Today, helper T cell differentiation is known to be much more complex and there are 
at least 6 subsets reported; Th1, Th2 Th17, iTregs, Th3 and Th9 (Fukaura et al., 1996; 
Jager et al., 2009; Mosmann and Coffman, 1989; Xing et al., 2011; Zhu and Paul, 2008). 
Each subset produces its signature cytokines and is responsible for mediating immune 
responses. Cytokine milieus and antigen stimulations determine the fate of naïve CD4+ T 
cells.  
 
Th1 cells 
       Th1 cells mediate cellular immune responses against intracellular pathogens by 
producing IFN-γ, IL-2 and lymphotoxin-α (LTα). IFN-γ is known as type II IFNs and 
activates macrophages through IFN-γ receptor signaling. This event mediates cellular 
immune response fighting against mycobacterial infections such as Leishmania major 
infections. LTα is another cytokine produced by Th1 cells which mediates inflammatory 
responses (Suen et al., 1997). Excess Th1 response can cause tissue damages which lead 
to autoimmune diseases too. For example, higher levels of LTα is detected in multiple 
 3 
sclerosis patients, suggesting LTα is involved in the disease progression. Suen et al. has 
found that LTα deficient mice are resistant to experimental autoimmune 
encepahalomyelitis (EAE), suggesting that LTα mediates EAE progression (Suen et al., 
1997). 
       Th1 cells express a transcription factor, T-bet which is induced by IFN-γ during Th1 
differentiation (Szabo et al., 2000). Ectopic expression of T-bet is sufficient to 
differentiate naïve CD4+ T cells into Th1 cells. It promotes IFN-γ production and inhibits 
production of IL-4, which is known as Th2 cytokine (Yin et al., 2002). Finotto et al. have 
shown that T-bet deficient mice develop an asthma like phenotype (Finotto et al., 2005). 
These data suggest that fine balance of Th1 cells against Th2 cells is critical to maintain 
immune homeostasis.  
 
Th2 cells 
       Th2 cells mediate humoral immune responses and are responsible for eliminating 
extracellular pathogens, such as helminth, by producing IL-4, IL-5, IL-10 and IL-13 
(Abbas et al., 1996; Glimcher and Murphy, 2000). Gros et al. and Swain et al. have 
shown that naïve CD4+ T cells preferentially differentiate into IL-4 producers under anti-
CD3 antibody stimulation in the presence of IL-4 in vitro (Gross et al., 1993; Swain et al., 
1990). They also show that this culture condition inhibits cells producing IFN-γ and IL-2.   
       Th2 cells express a transcription factor GATA-3 and expression of GATA-3 is 
upregulated during Th2 differentiation (Kurata et al., 1999; Zhu et al., 2001). IL-4 
mediates IgE class switching in B cells (Shimoda et al., 1996). IgE is known to bind to 
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FC receptor on basophils and mast cells (Schulman et al., 1988). This event leads to 
secretion of histamine from these cells, hence excess Th2 responses are often linked to 
induction of asthma and other allergic diseases (Barnes, 2001; Zhou et al., 2001).  
 
Th17 cells 
       Th17 cells mediate an inflammatory response by producing IL-17 (Ivanov et al., 
2006). Naïve CD4+ T cells can differentiate into Th17 in the presence of TGF-β and IL-6 
in vitro (Bettelli et al., 2006; Mangan et al., 2006; Veldhoen et al., 2006). Th17 cells do 
not produce IL-4 or IFN-γ, so it is considered a distinct subset from Th1 or Th2. IL-23 is 
another critical cytokine for Th17 (Aggarwal et al., 2003). Recent studies suggest that IL-
23 is not required for Th17 differentiation but is important for maintenance and 
proliferation of Th17 cells (Aggarwal et al., 2003; Bettelli et al., 2006; Veldhoen et al., 
2006). Th17 cells express an orphan nuclear transcription factor, RORγt (Ivanov et al., 
2006). RORγt directly activates transcription of IL-17 and it is required for Th17 
induction (Manel et al., 2008). Further, ectopic expression of RORγt makes CD4+ T cells 
Th17 like phenotype, suggesting that RORγt is sufficient to induce Th17 (Ivanov et al., 
2006; Sofi et al., 2010).  
       The importance of IL-17 signaling during infections was delineated using mouse 
models. Ye et al. showed that IL-17 deficient mice became extremely sensitive to 
intranasal Klebsiella pneumoniae compared to wild type mice using a model of Klebsiella 
pneumoniae lung infection (Ye et al., 2001). IL-17 was important to clear the pathogens. 
On the other hand, accumulating evidence suggests that IL-17 is also involved in the 
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development of autoimmune diseases, such as rheumatoid arthritis and multiple 
sclerosis (Gold and Luhder, 2008; Hofstetter et al., 2005; Kotake et al., 1999; Nakae et 
al., 2003). For example, Komiyama et al. showed that IL-17 knockout mice exhibit a 
delayed onset of experimental autoimmune encephalomyelitis (EAE) (Komiyama et al., 
2006). Blockade of IL-17 signaling using anti-IL-17 neutralizing antibody experiments 
also showed delayed Type I diabetes in the NOD mouse model (NOD), which produced 
increased levels of IL-17 (Emamaullee et al., 2009).  
      In humans, Zao et al. showed that AID patients had higher frequencies of Th17 cells 
(Zhao et al., 2010). Furthermore, Wong et al reported that increased levels of IL-17 in 
plasma from SLE patients compared to healthy donors (Wong et al., 2008).  
 
Th9 cells 
       Th9 is the most newly identified helper T cell subset, which produces IL-9. IL-9 is a 
pleiotropic cytokine which influences multiple cell types including T cells, B cells and 
Mast cells. For T cells, IL-9 is important for cell growth and can promote Th17 
differentiation (Elyaman et al., 2009; Nowak et al., 2009; Schmitt et al., 1994). For Mast 
cells, IL-9 increases their activity and also works as a growth factor (Wiener et al., 2004). 
IL-9 producing CD4+ T cells were originally classified as a part of the Th2 subset, 
however it is now considered as a distinct population from Th2 (Soroosh and Doherty, 
2009).  Naïve CD4+ T cells differentiate to Th9 in the presence of IL-4 and TGF-
β (Schmitt et al., 1994). Recently, PU.1 was characterized as the Th9 hallmark 
transcription factor (Chang et al., 2009; Chang et al., 2005). PU.1 directly controls IL-9 
gene transcription but also represses Th2 cytokine production (Chang et al., 2010).  
 6 
       IL-9 is thought to be involved in proinflammatory responses. Temann et al. showed 
that overexpression of IL-9 in lungs of transgenic mice caused asthma symptoms such as 
mucus production and subepithelial fibrosis (Temann et al., 2002). Further, Kearly et al 
showed that mice treated with IL-9 neutralizing antibody ameliorated allergy 
inflammation using an acute inflammatory mouse model challenged with house mite 
allergen (Kearley et al., 2011).  
 
REGULATORY T CELLS FOR TOLERANCE 
 
Introduction 
       In the early 1970s, the concept of peripheral tolerance attracted attention.  Gershon 
and Kondo found that a T cell subset, termed suppressor T cells, dampened immune 
responses (Gershon and Kondo, 1970). It was reported that the I-J molecule, which was 
supposed to be located on MHC gene complex, played a key role in exerting immune 
suppressive functions. However it turned out to be not true, and it was realized that such 
I-J molecules did not exist after extensive studies using molecular biology techniques 
(Kronenberg et al., 1983). In 1995, Sakaguchi et al. drew renewed attention for the 
concept of suppressor T cells (Sakaguchi et al., 1995). They discovered that CD4+CD25+ 
T cells have suppressive ability against immune responses. CD25 is an IL-2 receptor 
α chain and 5-10% of CD4+ T cells express CD25 under the naïve state while all CD4+ T 
cells upregulate surface expression of CD25 after TCR activation (Levings et al., 2001; 
Sakaguchi et al., 1995). They performed a cotransfer of CD4+CD25- and CD4+ CD25+ T 
cells into athymic mice and found that the mice which only received CD4+CD25- T cells 
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developed severe autoimmune symptoms including colitis and auto-antibody production 
(Sakaguchi et al., 1995). This experiment suggests that CD4+CD25+ T regulatory (Treg) 
cells indeed have suppressive functions to control immune responses. Later, accumulated 
evidence suggested that IL-2 receptor α chain (CD25) was not only a Treg cell surface 
marker but also critical for development, survival and function of Treg cells (D'Cruz and 
Klein, 2005; Fontenot et al., 2005).  
      CD4+CD25+ Treg cells develop in the thymus. Itoh et al. found that TCR transgenic 
mice which also lack Rag expression did not develop Tregs, suggesting that Tregs need 
TCR specificity for cell development (Itoh et al., 1999). Recent studies suggested that 
TCR repertoires between CD4+CD25+ Treg cells and CD4+CD25-T cells were comparable 
but distinct by sequencing the variable region of TCR α chain (Kuczma et al., 2009; 
Madakamutil et al., 2008; Singh et al., 2010b).  
 
Foxp3 
       Although CD4+CD25+ T cells were discovered as a CD4+ T cell subset which had 
suppressive functions and termed regulatory T cells by the Sakaguchi group, it was not 
understood what controlled suppressive function of CD4+CD25+ Treg cells. 
        Scurfy mice came about by a spontaneous mutations on the X choromosome. These 
mice exhibit autoimmune disease symptoms including splenomegaly and 
lymphadenopathy. In 2001, Benett et al. discovered the scurfy mice had mutations in the 
foxp3 gene (Bennett et al., 2001). Hori et al. then reported that Foxp3 was specifically 
expressed in the CD4+CD25+ Treg cell population (Hori et al., 2003). Further, they 
showed that overexpression of Foxp3 rendered non-Treg cells (CD4+CD25- T cells) to a 
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Treg-like phenotype with suppressive functions (Hori et al., 2003). Also, Fontenot et al. 
showed that ectopic expression of Foxp3 conferred suppressor function on peripheral T 
cells (Fontenot et al., 2003). In humans, autoimmune syndrome X-linked neonatal 
diabetes mellitus, enteropathy and endocrinopathy (IPEX) patients have multiple 
mutations in the foxp3 gene, suggesting there is a link between foxp3 mutations and 
autoimmune disease (Lopes et al., 2006; Myers et al., 2006). Furthermore, forced 
expression of Foxp3 using transgenic mice rendered mice more susceptible to virus 
infection challenges and showed reduced T cell numbers in the spleen and lymph nodes 
while T cell development occurred normally (Guo et al., 2010).  These finding suggested 
that Foxp3 was a master regulator of Treg cells.  Foxp3 is a transcription factor and a 
member of the forkhead family (Ziegler, 2006). It has a fork head (FKH) domain which 
binds to core DNA sequences (Coffer and Burgering, 2004; Lin and Peng, 2006). 
Members of the Foxp3 family function as both transcriptional activators and repressors. 
Accumulated evidence suggests that Foxp3 also works as transcriptional activator and 
repressor. For example, the il-2 gene is a known target of Foxp3 and its gene expression 
is negatively regulated in Treg cells (Fontenot et al., 2003; Hori et al., 2003). Schubert et 
al. showed that ectopic expression of Foxp3 in Jurkat cells resulted in downregulation of 
il-2 (Schubert et al., 2001). Recently, mechanisms that make Foxp3 repress the il-2 gene 
have been proposed. Schubert et al. showed that the il-2 promoter contained a forkhead 
binding sequence adjacent to the NFAT binding site, therefore they proposed a model in 
which Foxp3 competes for the binding site with NFAT thus repressing il-2 transcription 
(Schubert et al., 2001). Betteli et al. showed that NFAT and Foxp3 interact in a cell free 
system (in cell lysate), therefore they proposed the model where Foxp3 sequestered 
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NFAT thus inhibiting NFAT binding to the il-2 promoter (Bettelli et al., 2005). Further, 
Wu et al. showed that mutations in the NFAT interaction site of Foxp3 upregulated il-2 
gene expression (Wu et al., 2006). This also supports the model that Foxp3 inhibits 
NFAT binding to the il-2 promoter by directly interacting with NFAT. 
   Additionally, other Treg function related genes such as CD25 and CTLA4 are known to 
be upregulated by Foxp3 while expression of IL-4, IFN-γ genes is repressed (Ziegler, 
2006). 
 
Suppressive function of Treg cells 
       There have been multiple mechanisms proposed for CD4+CD25+Treg cell 
suppressive functions.  Hori et al. showed that Treg cells required antigenic stimulation 
via TCR to exert their suppressive function against responder cells (Hori et al., 2003). 
Takahashi et al. demonstrated that when Treg cells and responder cells (non-Treg cells) 
were separated using permeable membrane, Treg cells were not able to suppress 
proliferation of responder cells (Takahashi et al., 2000). Further, Gondek et al. showed 
that culture supernatant of antigen-stimulated Treg cells failed to suppress responder cells 
(Gondek et al., 2005). These results indicated that Treg cells suppress responder cells in a 
cell contact dependent manner.  
      Treg cells do not produce IL-2, however they express high levels of IL-2 receptor α 
chain, CD25 on the cell surface. Therefore, Padiyan et al. proposed the model that Treg 
cells used up IL-2 thus causing deprivation of IL-2 for responder cells leading to 
apoptosis (Pandiyan et al., 2007). They showed that the addition of exogenous IL-2 
rescued responder T cells from apoptosis and provoked Treg cell suppressive functions. 
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       The interaction of Treg cells and antigen presenting cells (APCs) has also been 
proposed to make up a suppressive environment. Oderup et al. found that Treg cells 
downregulated B7 costimulatory molecules expressed on DCs, suggesting that Treg cells 
reduced DC function thus preventing activation of responder cells (Oderup et al., 2006). 
Further, Treg cells activated DCs to upregulate expression of the enzyme indoleamine 
2,3-dioxygenase (IDO) (Fallarino et al., 2003; Grohmann et al., 2003). IDO bears off 
tryptophan by catabolizing the conversion of tryptophan to kyurenine, which is toxic to T 
cells (Mellor and Munn, 2004). Hence, responder cells lack the essential amino acid 
tryptophan and are exposed to kyurenin thus eliminating responder cells. 
     Cytokine secretion is also proposed to be one of Treg cell suppressive mechanism. 
Nakamura et al. demonstrated that membrane bound TGF-β expressed on Treg cells were 
essential for Treg cell suppressive function (Nakamura et al., 2001). Further, IL-10 and 
galectin were proposed to be involved in Treg cell suppressive function (Sugimoto et al., 
2006).  
      Together, these findings suggest that Treg cells suppress the immune response by 
multiple mechanisms in a direct or indirect manner. 
 
Inducible Treg (iTreg) cells 
       Naïve CD4+ T cells can differentiate to inducible Treg (iTreg) cells when TGF-β is 
present during antigen stimulation. iTreg cells also express Foxp3 as do Treg cells and 
exert suppressive function (Knoechel et al., 2005). However, Foxp3 expression in iTreg 
cells is not stable as nTreg cells. Floess et al. showed that iTreg cells which were 
generated under TCR stimulation in the presence of TGF-β, reduced Foxp3 expression 
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and suppressive function when they were restimulated in the absence of TGF-β (Floess 
et al., 2007). iTreg cells are preferentially generated in gut associated lymphoid organs, 
since TGF-β level is high in these area (Chen et al., 2003; Selvaraj and Geiger, 2007). 
Constant antigen exposure such as commensal bacteria or food antigens is also preferred 
condition for iTreg cell induction (Kretschmer et al., 2005; Mucida et al., 2005). 
 
 
T CELL RECEPTOR (TCR) PROXIMAL SIGNALING 
 
Introduction 
        As mentioned above, T cells recognize antigens using its surface expressed TCR, 
which initiates activation of cells thus leading to cell proliferation and cytokine 
production. At the molecular level, multiple proteins form signaling cascades and convert 
input TCR stimulation signals into output such as cytokine production.       
       Ligation of TCRs to their cognate antigens presented on MHC class II initiates TCR 
signaling cascade by activating receptor associated src family phosphotyrosine kinases, 
LCK. LCK then phosphorylates immunoreceptor tyrosine based activation motif (ITAM) 
on TCRζ chains in the CD3/TCR complex, thus making binding site for the dual src 
homology 2 (SH2) domain of src family kinase, the tyrosine kinase ζ- associated protein 
70 kDa (ZAP-70) (Iwashima et al., 1994; Kane et al., 2000; Straus et al., 1996). This 
event recruits ZAP -70 to the plasma membrane and activates ZAP-70.  Activation of 
ZAP70 then leads to phosphorylation of multiple side adopter proteins, the linker for 
activation of T cells  (LAT) and induces the formation of protein complex with other 
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adopter proteins including Grb-2, SHC, SLP76 by recruiting them to its 
phosphorylated sites (Buday et al., 1994; Gilliland et al., 1992; Zhang et al., 1998).  
       Son of sevenless (SOS) is a substrate for Grb-2 and is recruited to the plasma 
membrane following activation of Grb2 in the LAT complex. Activated SOS by 
phosphorylation then activates a Ras guanyl nucleotide exchange factor thus leading to 
Erk activation (Ravichandran et al., 1995; Xavier et al., 1998). 
       Phospholipase C-γ (PLC) is also one of the proteins which make a complex with 
LAT following LAT activation and is activated by phosphorylation in this protein 
complex (Nishibe et al., 1990). Activated PLC-γ then produces DAG and IP3 by cleaving 
phosphatidylinositol-4,5-bis phosphate (PIP2) (Nishibe et al., 1990). IP3 results in the 
increase of the intracellular calcium concentration [Ca2+] leading to nuclear translocation 
of the transcription factor, NFAT (Crabtree, 1999; Stankunas et al., 1999). DAG activates 
another Ras activator, RasGRP1 thus leading to the activation of Ras-Erk pathway (Ebinu 
et al., 2000).  
    One of most well studied outputs upon TCR stimulation was IL-2 production. IL-2 was 
originally identified as a T cell growth factor and essential for T cells to become effector 
cells and proliferate (Waldmann et al., 2001). Upon TCR activation, il-2 transcription is 
initiated by transcription factors including NFAT and AP-1 (Jain et al., 1995). NFAT is 
activated via the calcium signaling pathway and AP-1 is regulated via the Ras-Erk 
pathway. Erk activation leads to upregulation of c-Fos, which forms the AP-1 complex 
(Karin et al., 1997). Therefore, both the Ras-Erk signal and calcium signal regulate 
production of IL-2 in response to TCR stimulation.  
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RasGRP1 
        RasGRP1 was originally identified from brain and T cell cDNA library by selecting 
Ras activation related genes (Ebinu et al., 2000; Tognon et al., 1998). Ebinu et al. showed 
that the catalytic domain of RasGRP1 promoted activation of H-Ras in vitro using H-Ras 
overexpressed Rat2 cells (Ebinu et al., 2000). Further, they demonstrated that RasGRP1 
translocate to plasma membrane with PMA treatment followed by activation of Erk. They 
also characterized the catalytic domain by homology search of amino acids and identified 
that it contains CDC25, named for the prototypic Ras activator from Saccharomyces 
cerevisiae, and Ras exchange motif (REM) domain.  Shortly thereafter, Lorenzo et al 
demonstrated that RasGRP1 possessed C1 domain and bound to DAG and DAG analog, 
PMA (Lorenzo et al., 2000). Further, they tracked RasGRP1 localization by 
overexpressing RasGRP1- GFP fusion in Hela cells and showed that RasGRP1 
translocated to plasma membrane in response to PMA stimulation. These data suggest 
that RasGRP1 activated Ras in response to DAG.  
      RasGRP1 is dominantly expressed in T cells among RasGRP family (RasGRP1, 2, 3, 
4) and multiple T cell lines also express RasGRP1 (Ebinu et al., 2000). Especially, Jurkat 
T cell lines have been used to investigate a role of RasGRP1 in T cells. Ebinu et al. 
showed that over expression of RasGRP1 in Jurkat cells resulted in enhanced sensitivity 
to TCR stimulation of Ras-Erk pathway (Ebinu et al., 2000). Further, they showed that 
overexpression of RasGRP1 led to increased IL-2 production. Roose et al. reported that 
RasGRP1 deficient Jurkat cell lines had decreased activity of Ras-Erk pathway and 
decreased expression of CD69, which is early T cell activation marker in response to 
TCR stimulation (Roose et al., 2005). These data suggest that RasGRP1 links the signal 
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between PLC-γ and Ras. Although there is another Ras activator, SOS exists in T cells, 
these data suggest that RasGRP1 plays essential roles for activating Ras and is not 
compensated by SOS activity. This model was more clearly supported by using RasGRP1 
deficient mice.  
     Dower et al. engineered RasGRP1 deficient mice and demonstrated that RasGRP1 
was essential for thymocyte differentiation (Dower et al., 2000). They showed that 
RasGRP1 deficient mice exhibited abnormal thymocyte differentiation pattern. The 
CD4+CD8+ double positive T cell ratio substantially increased while single positive CD4+ 
or CD8+ T cells decreased compared to littermate control, suggesting that RasGRP1 
expression was required for positive selection during thymic development. In contrast, 
Normant et al. used RasGRP1 transgenic mice which overexpress RasGRP1 under 
control of the proximal LCK promoter (Norment et al., 2003). T cells which lack 
expression of Rag1 cannot under go V, (D), J gene rearrangement, therefore they cannot 
undergo development process in thymus (Swat et al., 1996). However, RasGRP1 
transgenic mice in Rag1 knockout background exhibited single positive CD8+ T cells, 
suggesting that RasGRP1 affects thymocyte development (Norment et al., 2003). 
       Dower et al. showed that RasGRP1 knockout mice have splenomegaly and 
autoimmune lymphoproliferative disorder (Dower et al., 2000). These mice also had 
antinuclear antibodies. These data suggest that the lack of RasGRP1 expression in T cells 
leads to expansion of T cells in periphery thus influencing to B cells. Since RasGRP1 
deficient mice lack RasGRP1 expression in whole body, Layer et al. further tested loss of 
RasGRP1 effect specifically on T cells (Layer et al., 2003). They adoptive transferred T 
cells isolated from lag mice,which has mutations in rasgrp1 gene, into T and B cell 
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deficient mice (RAG knockout mice). The recipient mice also developed autoimmune 
lymphoprolifarative disease, which suggested that loss of RasGRP1 expression in T cells 
causes pathogenesis.  
 
IMMUNE HOMEOSTASIS 
 
TGF-β in immune homeostasis 
       TGF-β is a pleiotropic cytokine which mediates multiple physiological functions 
such as proliferation, apoptosis and differentiation and is produced by many cell types 
including lymphocyte (Bommireddy and Doetschman, 2004).  TGF-β is also known as an 
essential factor to keep immune homeostasis (Gorelik and Flavell, 2002).  
       T cells dominantly produce TGF-β 1 among TGF-β family, TGF-β 1, 2 and 3 (Li et 
al., 2006). The role of TGF-β 1 in immune homeostasis and peripheral tolerance has been 
demonstrated using TGF-β1 deficient mice or TGF-β receptor deficient mouse models. 
Kukarni et al. and Shull et al. engineered TGF-β 1 deficient mice and showed that these 
mice developed an excessive inflammatory response and multifocal inflammatory disease 
and died at the age of 3 to 5 weeks (Kulkarni et al., 1993; Kulkarni and Karlsson, 1993; 
Shull et al., 1992).  Since T cells have been known to be essential for mediating immune 
disorders, it was expected that loss of TGF-β 1 caused immune disorders in a T cell 
dependent manner. Later, Gorelik et al. engineered transgenic mice which expressed 
dominant negative form of human TGF-β receptor II under control of the CD4 promoter 
(Gorelik and Flavell, 2000). Hence, TGF-β signaling is blocked specifically in T cells in 
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these transgenic mice. They showed that these transgenic mice also developed 
lymphoproliferative disorders, which suggested TGF-β signaling in T cells was required 
for regulating immune homeostasis. Li et al. further investigated the definitive role of 
TGF-β signaling using conditional TGF-β receptor knockout mice crossed with CD4 cre 
mice (Li et al., 2006). These mice lacked expression of TGF-β receptor II in T cells. 
These mice also exhibited lymphoproliferative disorders and lethal autoimmunity. This 
result also supports the idea that TGF-β signaling in T cells is required for regulating 
immune homeostasis. 
         It is now widely accepted that regulatory T cells are essential for maintaining 
peripheral tolerance. Li et al. showed that the number of Treg cells in the periphery 
substantially decreased in the conditional knockout mice, which lacked TGF-β signaling 
in T cells, while thymic Treg cell numbers were not affected, suggesting that TGF-
β signaling affected maintenance of Treg cells (Li et al., 2006). Further, they showed that 
TGF-β receptor deficient Treg cells proliferated more than wild type Treg cells in 
response to TCR stimulation, suggesting TGF-β signaling was suppressing Treg cell 
proliferation. To address whether the loss of peripheral tolerance in these mice is due to a 
decrease in the number of Treg cells or intrinsic effect of other effector T cells, Li et al. 
performed adoptive transfer experiment that transferred wild type Treg cells into neonatal 
TGF-bRII deficient mice. If a reduced number of Treg cells was the cause of autoimmune 
disorder in TGF-bRII deficient mice, transferred wild type Treg cells into the mice would 
be expected to rescue these mice from developing autoimmune disease. However, these 
mice still developed an autoimmune disease and transferred wild type Treg cells did not 
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suppress T cell activation in the host mice, which suggested that Treg cells are not only 
mechanisms to keep immune homeostasis, but also that TGF-β signaling in T cells 
possessed intrinsic effect leading to peripheral tolerance.  
       In addition to nTreg cells produced in thymus, naïve T cells also can be differentiated 
to Foxp3+ Treg cells referred to as inducible Treg (iTregs) cells. In vitro, naïve CD4+ T 
cells are differentiated to iTregs with TCR stimulation in the presence of TGF-β (Chen et 
al., 2003; Wan and Flavell, 2005). Tone et al. showed that TGF-β induces Foxp3 
expression through SMAD3 association with Foxp3 promoter (Tone et al., 2008). In an 
vivo mouse model, Peng et al. demonstrated that overexpression of TGF-β 1 in pancreatic 
islets resulted in expanded CD4+Foxp3+Treg cells and rescued NOD mice from 
developing diabetes (Peng et al., 2004).  These data suggest that TGF-β induces Treg 
cells thus maintaining peripheral Treg cells not only influencing nTreg cells. 
       TGF-β can influence naïve CD4+ T cell differentiation into other helper T cell subset 
besides iTreg cells. Betteli et al. showed that in the presence of IL-6, TGF-β can convert 
naïve T cells into Th17 and iTreg differentiation was blocked (Bettelli et al., 2006). Th17 
produces signature cytokine, IL-17 and leads to proinflammatory response (Bettelli et al., 
2006). Further, Gorelik et al. reported that TGF-β inhibited Th1 and Th2 differentiation 
by downregulating expression of their hallmark transcription factors, T-bet and GATA-3 
(Gorelik et al., 2000). This suggests that TGF-β can also contribute to inflammatory 
responses rather than keep peripheral tolerance.  
      The ligand, TGF-β 1 is secreted by T cells as homodimer but as an inactive form by 
associating with homodimer of latency associated protein (LAP) (Annes et al., 2003). To 
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initiate TGF-β signaling cascade, LAP has to be removed from TGF-β inactive form 
by integrins or matrix proteins such as Thrombospondin-1 (TSP-1) (Masli et al., 2006; 
Yehualaeshet et al., 1999).  
       TGF-β signaling is initiated when active form of TGF-β binds to TGF-β type II 
receptor and results in phosphorylation of serine /threonine kinase in Type II receptor 
kinase cytoplasmic domain. This event results in the engagement of tetrameric receptor 
complex of TGF-β receptor type I and type II, activating type I receptor serine /threonine 
kinase in the cytoplasmic region. Phosphorylated Type I receptor kinase then activates 
transcription factors, SMAD proteins thus eliciting multiple cellular functions by 
activating gene transcriptions (Bommireddy and Doetschman, 2004).  
 
Antigen induced cell death (AICD) in immune homeostasis 
      Activation induced cell death (AICD) is one of the mechanisms to keep immune 
homeostasis by decreasing T cell number in the periphery due to apoptosis. Shi et al. 
originally used the term AICD to describe the phenomenon that the ligation of the TCR 
on thymocytes leads to apoptotic cell death (Shi et al., 1989). At present, accumulating 
evidence suggests that mature T cells also can undergo AICD. An in vitro setting of 
AICD refers to a death caused by restimulation of activated T cells. To stimulate T cells 
in vitro, antigenic stimulation can be mimicked by using anti-CD3 antibody activating 
through the TCR and anti-CD28 antibody activating the CD28 costimulatory signal. In an 
AICD in vitro model, T cells are stimulated with anti-CD3 and anti-CD28 for several 
days, then restimulated with anti-CD3 or PMA and ionomycin. PMA is a diacylglycerol 
analog and ionomycin is an ionophore which increases intracellular calcium 
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concentration. Treating T cells with these chemicals also resembles TCR activation 
(Krammer, 2000).  
       In 1991, Lenardo et al. demonstrated that restimulation of T cells induced cell 
surface expression of Fas ligand leading to apoptosis by using T cell hybridoma 
(Lenardo, 1991).  Fas is a death receptor which belongs to the tumor necrosis factor 
receptor (TNFR) family and it possesses a death domain in the cytoplasmic tail of the 
intracellular region (Nagata, 1997). The ligation of Fas and Fas ligand leads to activation 
of Fas-associated death domain (FADD) followed by the formation of death inducing 
signaling (DISC) complex (Kischkel et al., 1995). The DISC complex then activates 
caspase 8 and induces apoptosis in T cells. There are soluble form and membrane bound 
form of Fas ligand expressed by alternative splicing. LA et al. showed that membrane 
bound form of Fas ligand was required to cause apoptosis in T cells by using mice which 
lack either the soluble form or the membrane bound form of Fas ligand (LA et al., 2009). 
Lenardo et al. showed that Fas mediated AICD was initiated in an IL-2 dependent 
manner (Lenardo, 1991). As described above, IL-2 is a cytokine produced by T cells and 
is known to be important factor for cell survival.  Further, Refaeli et al. showed that IL-2 
signaling upregulates the transcription and cell surface expression of Fas ligand thus 
inducing apoptosis (Refaeli et al., 1998). They used IL-2 knockout mice and showed that 
the IL-2 deficient CD4+ T cells did not upregulate cell surface expression of Fas ligand 
and became resistant to AICD. These data surprisingly suggest IL-2 signaling is not only 
a cell survival factor but also an important factor to induce AICD.  
        Mutant mice which have mutations in fas or fas ligand genes have been used to 
study the effect of Fas/ Fas ligand pathway. Lpr mice have mutations in fas gene locus 
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and do not produce functional Fas.  Gld mice have mutations in fas ligand gene locus 
and do not produce functional Fas ligand (Cohen and Eisenberg, 1991). These mice 
develop lymphoadenopathy with accumulated T cells and produce autoreactive 
antibodies. In human, Aspinall et al. reported that autoimmune lymphoproliferative 
syndrome (ALPS) patients had mutations in the fas gene (Aspinall et al., 1999). This 
evidence suggests that Fas/ Fas ligand signaling plays a critical role in maintaining 
immune homeostasis in the periphery.  
       Recent studies have shown that a mechanism other than Fas/ Fas ligand interaction is 
also involved in AICD in T cells. Hildeman et al. showed that lpr and gld mice were 
sensitive to T cell death induced by staphylococcal enterotoxin B (SEB), suggesting T 
cell death with SEB activation was induced in a Fas/FasL independent manner (Hildeman 
et al., 2002). Further, they found that Bcl-2 interacting mediator of cell death (Bim) is 
responsible for this apoptosis induced by SEB activation using T cells isolated from Bim 
knockout mice.  Snow et al. reported that Bim also played an important role in inducing 
AICD. They knocked down Bim expression in primary human T cells isolated from 
healthy donors and showed that T cells, which lacked Bim expression were rescued from 
AICD in vitro (Snow et al., 2008). They further found that T cells derived from ALPS 
patients expressed lower level of Bim and the cells were more resistant to AICD in vitro.  
      Bim is a member of BCL-2 family and BH-3 only protein, which has only one of Bcl-
2 homology region, BH-3. BCL-2 family mediates intrinsic apoptosis associated with 
mitochondrial membranes and at least 20 family members have been identified (Gross et 
al., 1999). Some of them are constitutively expressed on mitochondrial membrane or 
translocate to mitochondria upon stimulation. They are separated into two groups by their 
 21 
function, pro-apoptotic and anti-apoptotic. Anti-apoptotic proteins include BCL-2, 
BCL-X and BCL-W. Pro-apoptotic proteins include Bim, BAK, BAD and BAX. Bim 
antagonizes BCL-2 which inhibits BAK and BAX pro-apoptotic function by associating 
with them (O'Connor et al., 1998). Hence, Bim releases Bak and BAX and leads to 
activation of caspase 9 and apoptosis in cells.      
           Bim expression is regulated at both the transcriptional and the post-transcriptional 
level. Bim has three isoforms, Bim EL, Bim L, and Bim S (O'Connor et al., 1998). These 
isoforms are produced by alternative splicing and all of them can induce apoptosis. In T 
cells, Bim is upregulated upon TCR stimulation through protein kinase C and in a 
calcineurin dependent manner (Sandalova et al., 2004).  
        Bim deficient mice exhibit lymphadenopathy and contain increased number of T 
cells and B cells compared to littermate controls (Bouillet et al., 1999). These mice also 
develop severe autoimmune disease phenotypes as seen in Fas, Fas ligand mutant mice 
(lpr, gld mice), suggesting that Bim also plays a critical role in mediating immune 
homeostasis.  
       Recent studies suggest that Bim and Fas have a complementary effect. Hutcheson et 
al. generated mice which lacked expression of both Bim and Fas by crossing lpr and Bim 
knockout mice and showed that the mice exhibited much more severe autoimmune 
disease phenotype depicted by lymphoadenopahty compared to Bim or Fas single 
deficient mice (Hutcheson et al., 2008). These mice accumulated a large number of T 
cells and B cells in lymphoid organs and it expanded to half of the animal’s body mass. 
These data suggest Bim and Fas pathway has synergistic effect on developing 
autoimmune disease.  
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PROPOSED MODEL AND P53 DEPENDENT APOPTOSIS (PICA) 
 
      We previously discovered the phenomenon that non-Treg cells undergo apoptosis 
when CD4+ and CD8+ T cells are stimulated with plate-bound anti-CD3/anti-CD28 
antibodies coated on plastic plate in the presence of IL-2 over 4 days (Singh et al., 
2010a). Activation induced cell death (AICD) is a well known mechanism that causes T 
cell apoptosis. Boehme et al. showed that T cell blasts isolated from p53 deficient mice 
were sensitive to anti-CD3 antibody induced cell death, suggesting that AICD did not 
require p53 expression (Boehme and Lenardo, 1996). p53 is a transcription factor which 
is activated upon cellular stresses, including UV damage and inappropriate cell 
proliferative signals. p53 regulates cell cycle and other cellular functions (Levine, 1997).  
We showed that p53 deficient CD4+ T cells became resistant to apoptosis induced by 
plate-bound anti-CD3/anti-CD28 antibody stimulation, suggesting the apoptosis induced 
by this stimulation was in a p53 dependent manner and distinguishable from classical 
AICD.  Hence, we named this novel form of apoptosis caused by plate-bound anti-
CD3/anti-CD28 antibody stimulation “p53-induced CD28-dependent apoptosis” (PICA) 
to distinguish it from classical AICD (Singh et al., 2010a). Interestingly, CD4+CD25+ 
Treg cells were resistant to PICA and selectively expanded under PICA-inducing 
conditions while non-Treg cells (CD4+CD25- T cells) underwent massive apoptosis.  The 
Treg cell number increased 7,000 fold in 7 days under plate-bound anti-CD3/anti-CD28 
antibody stimulation.  
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       We further showed that PICA was induced in non-Treg cells in a Bim and Fas/ 
FasL dependent manner due to upregulation of each molecule upon plate-bound anti-
CD3/ anti-CD28 antibody stimulation by using Bim deficient and lpr (Fas mutant) mice. 
In contrast, Treg cells suppressed Bim and FasL expression under PICA inducing stimuli.  
      The p53 deficient mice were also equally susceptible to AICD compared to wild type 
mice. On the other hand, accumulated evidence suggests that the lack of p53 expression 
in mice leads to earlier onset or exacerbated autoimmune diseases in various mouse 
models. Simelyte et al. showed that experimental induced arthritis mice, which lack p53 
expression exhibited exacerbated disease symptoms compared to wild type mice 
(Simelyte et al., 2005). Okuda et al. used an experimental autoimmune encephalomyelitis 
(EAE) model, which showed p53 deficient mice injected with myelin oligodendricyte 
glycoprotein developed more severe disease than the wild type control (Okuda et al., 
2003).  Zheng et al. reported that p53 deficient mice are more susceptible to streptozocin-
induced diabetes which was used as a model for type I diabetes (Zheng et al., 2005). In 
humans, Maas et al. reported that peripheral blood mononuclear cells isolated from 
rheumatoid arthritis patients expressed lower level of p53 at the mRNA level compared 
to healthy donors in response to gamma-radiation (Maas et al., 2005). These observations 
suggest that p53 dependent cell death rather than AICD might be important to maintain 
immune homeostasis. However, it is not understood what causes dysregulation in 
immune homeostasis and exacerbated autoimmune disease phenotype in p53 deficient 
mouse models.  
          Our in vitro data using plate-bound anti-CD3/anti-CD28 antibody stimulation 
showed that p53 dependent apoptosis (PICA) caused apoptosis in non-Treg cells but 
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expand Treg cells, so it was predicted that PICA inducing condition would increase the 
ratio of CD4+CD25+ Treg cells to non-Treg cells (CD4+CD25- T cells). Hence, we 
propose the model that the differential survival mechanism between Treg cells and non-
Treg cells against PICA is important to balance Treg cells and non-Treg cells thus 
maintaining immune homeostasis. Therefore, we herein will determine the differential 
survival mechanisms of Treg cells and non-Treg cells using plate-bound anit-CD3/anti-
CD28 antibody stimulation. 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
Mice 
       BALB/c, C57BL/6 and CD4dnTgfbr2 were purchased from Jackson Laboratory (Bar 
Harbor, ME). RasGRP1 knockout mice were a gift from Dr. James C Stone (University 
of Alberta, Canada). All mice were maintained under specific pathogen-free conditions. 
All procedures were approved and monitored by the Institutional Animal Care and Use 
Committee of Loyola University Chicago. 
 
Flow cytometry 
      Fluorochrome-conjugated antibodies specific for Foxp3 (clone FJK-16s) and IL-17A 
(clone ebio17B7) (eBioscience, San Diego, CA), anti-CD4 (clone GK1.5) and anti-IL-9 
(clone RM9A4) (Biolegend, San Diego, CA), annexin V, 7-aminoactinomycin D (7AAD), 
anti-CD25 (7D4), anti-Fas (Jo2) and anti-FasL (MFL3) (BD Biosciences, San Jose, CA) 
were used in the experiments. Cells were pelleted by centrifugation at 1,500 rpm for 5 min 
at 4°C. 10 µl of culture supernatant from 24G2 hybridoma (FC receptor blocker) was added 
and tubes were kept at room temperature for 5min. Cells were then washed with FACS 
buffer (1% FCS, 0.1% sodium azide in 1× PBS). Cell surface staining was performed using 
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50 µl of antibodies (1:100 to 1:500 dilution in FACS buffer) for 30 min on ice. After 
staining, cells were washed with FACS buffer. For Foxp3 staining, cells were fixed and 
permeabilized using FOXP3 Staining Buffer Set (eBiosciences, San Diego, CA) as 
described in the manufacture’s protocol. Briefly, cells were washed twice with 1× PBS 
after cell surface staining followed by fixation with 300ul of 1× FixPerm buffer overnight 
at 4°C. The next day, cells were washed twice with FACS buffer and incubated with 1× 
permiabilization buffer for 10 min on ice. Cells were then stained with anti-Foxp3 antibody 
(diluted as 1:200) for 1 hour on ice followed by washing with FACS buffer. For annexin V 
and 7AAD staining, cells were stained in annexin binding buffer (10 mM HEPES pH7.4, 
140 mM NaCl, 2.5 mM CaCl2) with 7AAD (diluted as 1:50) and annexin V (diluted as 
1:50) for 15min at room temperature in the dark. Cells were kept on ice after staining and 
data was collected within 30min. Data was collected on a flow cytometer (FACS Canto II, 
BD Biosciences, San Jose, CA or an Accuri’s C6 flow cytometer, Accuri Cytometers, Ann 
Arbor, MI) and analyzed using FlowJo software (TreeStar, Ashland, OR). 
 
Cytokine staining 
       For intracellular cytokine staining, cells were harvested and restimulated with 50 ng/ml 
phorbol 12-myristate 13-acetate (PMA) (Fisher scientific, Pittsburgh, PA) and 1 µM 
ionomycin (Sigma-Aldrich, St. Louis, MO) in the presence of 2 µM monencin for 4 hours. 
Cells were then washed twice with 1× PBS followed by fixation using 4% 
Paraformaldehyde for 10 min at room temperature. Tubes were then filled with FACS 
buffer and kept overnight at 4 °C. The next day, cells were washed twice with FACS buffer 
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and permeabilized with 250 µl of permeabilization buffer (containing 50 mM NaCl, 
0.02% NaN3, 5mM EDTA, 0.5% TritonX, pH7.5) on ice for 10min. Cells were then washed 
twice with FACS buffer and incubated with 250 µl of 3% bovine serum albumin (BSA) for 
blocking. Intracellular staining with anti-IL-17 (diluted as 1:400) or anti-IL-9 (diluted as 
1:200) antibodies was performed on ice for 1hour followed by washing with FACS buffer. 
Data was collected on a flow cytometer (FACS Canto II, BD Biosciences) and analyzed 
using FlowJo software (TreeStar, Ashland, OR).  
 
Preparation of CD4+CD25+ Treg cells and CD4+CD25- T cells from the mouse spleen  
       Splenic CD4+ T cells were purified by depletion of non-CD4+ T cells by the panning 
method. Spleens were mashed using the frosted side of glass slides to release cells. 
Splenocytes were treated with ACK lysis buffer (Gibco, Grand Island, NY) for 1 min to 
remove red blood cells by hypotonic shock. Cells were washed with washing media 
(containing 1% FCS in RPMI1640) followed by an incubation with 20% of anti-CD8 
(using 3-155 hybridoma culture supernatant) on ice for 30 min. Cells were then washed 
twice with washing media. Washed cells were plated on goat anti-mouse immunoglobulin 
pre-coated plates and allowed to adhere to plate-bound anti-mouse immunoglobulin for 30 
min. Non-adherent cells were collected and this crude fraction of CD4+ T cells was then 
resuspended in sorting media (containing 2% FCS, 10mM Hepes, 4.2mM Sodium 
bicarbonate in Hanks balanced salt solution, 1× Hank’s buffer) at a concentration of 50× 
106 cells/ml and then labeled with fluorochrome-conjugated anti-CD4 and anti-CD25 
antibodies on ice for 45min. Cells were then washed with sorting medium. CD4+CD25- T 
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cells /CD4+CD25+ T cells were then sorted using a cell sorter (FACS ARIA, BD 
Biosciences, San Jose, CA or MoFlo cell sorter, Beckman Coulter, Brea, CA).  Sorted cells 
were kept overnight at 4°C in culture media and then used for experiments.  
 
Culture media 
       RPMI 1640 media supplemented with 10% FCS (Atlanta Biologicals, Lawrenceville, 
GA), β-mercaptoethanol (50 µM), glutamine, Hepes (10 mM), sodium pyruvate (1 mM), 
and non-essential amino acids (Invitrogen, Grand Island, NY) were used in the 
experiments. 
 
Treg cell expansion  
       Sorted CD4+CD25+ Treg cells resuspended into 5 mls of culture media with10ng/ml of 
mouse IL-2 (PeproTech, Rocky Hill, NJ) and were plated in 60 mm petri dishes (USA 
scientific, Orlando, FL) pre-coated overnight at room temperature with 2 ml of anti-CD3 
(clone 2C11) and anti-CD28 (clone 37-51) (Biolegend, San Diego, CA) antibodies (5µg/ml 
each) diluted in 0.1M Borate buffer (pH 8.5). After 4- 5 days of culturing, cells were 
scraped from dishes by pipetting and split into newly anti-CD3/ anti-CD-28 pre-coated 
dishes (~2.5× 106 cells per plate). Cells were harvested by pipetting after 2-3 days of 
culture. 
 
Non-Treg cell (CD4+CD25- T cells) expansion  
       The anti-CD3/anti-CD28 coated beads were used for stimulation and expansion of 
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CD4+CD25- T cells. 100 µl of 4.5 µmeter polystyrene beads (Polysciences, Inc, 
Warrington, PA) (containing ~2.5× 107 beads) were resuspended in 1ml borate buffer 
(0.1M Boric acid, pH 8.5) containing anti-CD3 (10 µg/ml) and anti-CD28 (10 µg/ml) 
antibodies and kept at room temperature overnight with gentle rocking. The next day, anti-
CD3 and anti-CD28 coated beads were washed three times with borate buffer to remove 
unbound antibodies followed by blocking with 10% FCS for 30 min. The anti-CD3/ anti-
CD28 antibodies coated beads were stored in 10% FCS culture medium. Sorted 
CD4+CD25- T cells (1× 106 cells) were pelleted and resuspended in 50 µl culture medium 
containing 4× 106 pre-coated beads. Cells were then kept in a 37 °C water bath for 45 min 
to promote cell-bead contact. After 45 min of cell-beads incubation, cells bound to beads 
were then carefully transferred to 2 mls of culture media containing 10 ng/ml of IL-2.   
 
T cell receptor stimulation using biotin-conjugated anti-CD3 antibody cross-linked by 
avidin 
            CD4+CD25- T cells or CD4+CD25+ Treg cells were sorted on FACS Aria and 
expanded in vitro for 7 days as described above. After expansion, cells were washed three 
times with wash media (RPMI1640 containing 1% FCS) to remove stimulation and then 
cultured in 10% FCS complete media in the presence of 1ng/ml IL-2 for overnight. The 
next day, cells were resuspended in 10% FCS culture media. 5× 106 cells resuspended in 
1ml of 10% FCS culture media were allowed to sit in a 1.5 ml microcentrifuge tube and 
warmed for 10min in a 37°C water bath. Cells were then stimulated with 5 µg/ml functional 
grade biotin-conjugated anti-CD3 antibody (2C11) (eBioscience, Sandiego, CA) cross-
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linked by 5 µg/ml avidin egg (calbiochem, EMD Chemicals, Rockland, MA).  
 
T cell stimulation by plate-bound anti-CD3 and anti-CD-28 antibodies 
       Sorted CD4+CD25+ or CD4+CD25- T cells were placed into 60 mm dishes pre-coated 
overnight at room temperature (with 2 ml of anti-CD3, clone 2C11 and anti-CD28, clone 
37-51, Biolegend at concentration of 5 µg/ml each in 0.1M borate buffer pH 8.5) containing 
5 mls of RPMI culture media in the presence of recombinant IL-2 (10ng/ml). TGF-
β signaling in cell culture was blocked using 5 µg/ml anti-TGF-β 1, 2, 3 antibody (clone 
1D11) (R&D Systems, Minneapolis, MN) or 10 µM SB431542 (Sigma-Aldrich). 2.5 nM of 
recombinant human TGF-β (R&D Systems, Minneapolis, MN) was used as an active form 
of TGF-β. IL-4 signaling was blocked in cell cultures using 10% 11B11 hybridoma culture 
supernatant (which contains anti-IL-4).  
 
Western blot 
        Equal number of cells was lysed in SDS sample buffer (2% SDS, 125mM DTT, 10% 
glycerol, 62.5 mM Tris-HCl, pH 6.8).  Cell lysates were then boiled for 10 min and loaded 
onto 8-15% SDS PAGE gels.  After gel electrophoresis, separated proteins were transferred 
overnight onto PVDF membranes (Millipore, Birellica, MA) at 30 V at 4℃. Blotted 
membranes were then blocked with 5% skim milk in 1× TBST buffer (containing 20 mM 
Tris-Hcl pH6.8, 137 mM NaCl, 0.1% Tween 20) for one hour and probed with antibodies 
specific for phospho-ERK (clone E10), phospho-Mek, phospho-cRaf, Bim, Mek (Cell 
signaling technology, Danvers, MA), Erk (Millipore, Billerica, MA), Raf 1(clone C-20), 
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RasGRP (clone 199), Fas ligand (kay-10), Sos1 (clone C-23) (Santa Cruz 
biotechnology, Santa Cruz, CA), Ras (clone 18/Ras) (BD Biosciences, San Jose, CA), or β-
actin (clone AC15) (Sigma-Aldrich, St. Louis, MO). All antibodies were diluted in dilution 
buffer (containing 0.2-5% BSA, 0.1% sodium azide in TBST) for probing. The membranes 
were further probed with anti-rabbit or anti-mouse HRP conjugated secondary antibodies 
(Cell Signaling Technology). Signals were detected by enhanced chemiluminescence 
(ECL) plus western blotting detection reagents (GE Healthcare, Piscataway, NJ).  
 
Enzyme-linked immunosorbent assay (ELISA) 
         IL-17, IL-4, IFN-γ and IL-9 production was measured by enzyme-linked 
immunesorbent assay (ELISA). Purified or biotin conjugated antibodies specific for IL-4 
(clone 11B11) (Biolegend, San Diego, CA), IL-4-biotin (clone 13VD6-24G2), IFN-γ (clone 
R4-6A2) (eBioscience, San Diego, CA), IFN-γ-biotin (clone XMG1.2) (BD Biosciences, 
San Jose, CA) were used in these experiments. Mouse IL-17A ELISA MAXTM Standard 
Sets and mouse IL-9 ELISA MAXTM Set Deluxe (Biolegend, San Diego, CA) were used for 
detection of IL-17 and IL-9. ELISA for IL-4 and IFN-γ were performed in 96 well flat 
bottom ELISA microplates (BD Bioscience) coated with 50 µl of polyclonal anti-IL-4 
(1:500) or anti-IFN-γ antibodies (1:500) diluted in bicarbonate buffer (pH8.0) and 
incubated overnight at 4°C. Plates were washed the next day using washing buffer 
(containing 0.05% Triton× in 1× PBS) to remove unbound antibodies and then incubated 
with 50 µl of cell culture supernatants overnight at 4°C. Cell culture supernatant was 
removed by washing followed by incubation with biotin-conjugated anti-IL-4 and anti- 
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IFN-γ antibodies for 1 hour at room temperature. Excess antibodies were washed and 
plates were incubated with HRP conjugated avidin for 30 min at room temperature 
followed by washing wash buffer. Plates were then incubated with 50 µl of 3,3′,5,5′-
tetramethylbenzidine (TMB substrate) (Sigma Aldrich, St. Louis, MO) for a few minutes 
and then the enzyme reaction was stopped by adding 50 µl of stopping solution (containing 
2M H2SO4). Data was collected on microplate reader, KCjunior (Bio-Tek instruments, 
Winooski, VT) using 450 nm wavelength. Serial dilutions of standards were used to 
generate a standard curve which was then used to calculate cytokine concentration.  
 
Chromatin Immunoprecipitation (CHIP) Assay 
        A ChIP assay was performed using a ChIP assay kit (Usb, Cleveland, Ohio) as 
described in the manufacture’s protocol with some modifications. CD4+CD25+ Treg cells 
were sorted on a FACS Aria and then expanded in vitro for 7 days as described above. 1× 
107 Treg cellss were used for each set of experiments. Harvested cells were centrifuged at 
1,500 rpm for 5 min at 4°C followed by washing the cell pellet with 10 ml of 1× PBS 
(containing 2% FCS). Cells were then resuspended in freshly made 1% formaldehyde in 1× 
PBS (containing 2% FCS). Cells were incubated for 15min at room temperature with gentle 
rocking thoroughly on rotating shaker platform to promote crosslinking. This was followed 
by the addition of glycine to the cells for a final concentration of 0.125M for 5 min at room 
temperature to halt crosslinking. Cells were then washed twice with 10 ml of chilled 1× 
PBS (containing 2% FCS). Cells were pelleted and frozen in liquid nitrogen quickly and 
stored at -80°C for future use or lysed immediately in 1 ml of cell lysis buffer. Cell lysate 
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was sonicated for chromatin fragmentation using Sonifier250 (BRANSON, Fisher 
scientific, Pittsburgh, PA). The condition of sonication was optimized to make the 
chromatin DNA fragment size between 200 and 800bp. The optimized condition is Duty 
cycle 80%, Level 2.5 for 15 sec for 4 sets and Duty cycle 80%, Level 3.0 for 10sec once. 
Samples were chilled on ice for 2 min between each cycle. Samples were then centrifuged 
at 13,000 rpm at 4°C for 10 min and supernatants were transferred to a new 1.5 ml 
microcentrifege tubes. 100 µl of cell lysate (1× 106 cells) was diluted in 500 µl lysis buffer 
and pre-cleared by using 50 µl of pre-blocked beads with gentle rocking for 1 hour at 4°C. 
Beads were then centrifuged at 3,000 rpm for 5 min at 4°C and the supernatant was 
carefully transferred to new 1.5 ml microcentrifuge tube followed by incubation with 4 µg 
of rabbit polyclonal anti-Foxp3 antibody (Novus biologicals, Littleton, CO) or polyclonal 
rabbit IgG (Cell signaling technology, Danvers, MA) as a negative control overnight at 4°C 
with gentle agitation. The next day, samples were centrifuged at 3,000 rpm for 5 min at 4°C 
and were washed with 1 ml of lysis buffer for 10 min with gentle rocking followed by 
washing with 1 ml of high salt buffer, 1 ml of lithium salt buffer and 1 ml of TE buffer. 120 
µl of elution buffer was then added and the samples were incubated for 20 min on a 
rotisserie shaker at room temperature. Beads were pelleted by centrifuge at 3,000 rpm for 5 
min at room temperature and supernatants were transferred to a new 1.5 ml microcentrifuge 
tube. Beads pellets were again resuspended in 120 µl of elution buffer and incubated for 20 
min on rotisserie shaker at room temperature. Beads were centrifuged at 3,000 rpm for 5 
min at room temperature and supernatants were combined with 1st collection followed by 
incubation with 9 µl of 5 M NaCl overnight at 65°C to reverse crosslink. The next day, 
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DNA was purified using QIAquick PCR purification kit (QIAGEN, Valencia, CA) and 
eluted using 40 µl of 10 mM Tris-HCl, pH8.5. PCR was performed using TaKaRa ExTaq 
(Fisher Scientific) and primer sets (Table 1). 
 
Quantitative RT-PCR 
       Total RNA was isolated as described in the manufacture’s protocol (Ambion, Applied 
Biosystems, Carlsbad, CA). Cells were centrifuged at 3,000 rpm for 5 min at 4°C and lysed 
in 500 µl of TRI reagent (Ambion) by pipetting followed by an incubation for 5 min at 
room temperature. 200 µl of chroloform was added and the samples were incubated for 
10min at room temperature followed by centrifugation at 13,000 rpm for 10 min at 4°C. 
The top aqueous phase (~400 µl) was transferred to new tube and mixed with 400 µl of 
isopropanol followed by an incubation for 5 min at room temperature. Samples were then 
centrifuged at 13,000 rpm for 10 min at 4°C and washed with 500 µl of 70% EtOH. Total 
RNA was resuspended in 15-30 µl of RNase free water. 
       cDNA was synthesized from total RNA using OligodT primers and Superscript III 
cDNA synthesis kit (Invitrogen, Grand Island, NY). ~1 µg of total RNA was incubated 
with 1 µl of 50 µM oligo (dT) primers and 1 µl of 10 mM dNTP for 5 min at 65°C. 
Samples were then chilled on ice for 2 min and incubated with cDNA systhesis mix (1× RT 
buffer, 5 mM MgCl2, 10 mM DTT, 40 U RNaseOUT and 200 U SuperScriptIII RT) for 50 
min at 50°C. The reaction was then terminated by incubation at 85°C for 5 min and chilled 
on ice for 5 min. Remaining RNA was digested by incubation with 1 µl of RNaseH for 20 
min at 37°C. cDNA synthesis reaction was stored at -20°C. 
  
35 
       Realtime PCR was performed using MaximaTM SYBR Green qPCR master mix 
(Fermentus, Fisher scientific, Pittsburgh, PA) and primer sets (Table 1).  
 
Measurement of intracellular free calcium  
      CD4+CD25- T cells or CD4+CD25+ Treg cells were sorted on FACS Aria and expanded 
for 7 days as described above. After expansion, cells were washed three times with wash 
media (RPMI1640 containing 1% FCS) to stop stimulation and cultured in 10% FCS 
culture media in the presence of 1 ng/ml IL-2 overnight. The next day, cells were 
resuspended in 10% FCS culture media and loaded with 6 µl of 1 mM Fura-2 AM (at a 
final concentration of 6 µM) (Molecular probe, Invitrogen, Grand Island, NY) for 15 min at 
37°C in dark. Cells were then washed with 1× Hanks buffer (without calcium) (Gibco, 
Invitrogen, Grand Island, NY) to quench excess dye and then resuspended in 1 ml of 1× 
Hanks buffer (without calcium). Intracellular free calcium was measured by transferring 
cells into a cuvette of a spectrofluorophotometer (RH500, Shimadzu, Columbia, MD) and 
the data were calculated at 340 nm/380 nm excitation. First, the spectrofluorophotometer 
was paused after monitoring the basal level of [Ca2+] for 60 sec. The 
spectrofluorophotometer was then resumed and cells were stimulated with 5 µg/ml 
functional grade biotin-conjugated anti-CD3 antibody (2C11, eBioscience, San Diego, CA) 
crosslinked by 5 µg/ml avidin egg (calbiochem, EMD chemicals, Philadelphia, PA). Data 
were collected for 10 min after stimulation.  
 
Statistical analysis 
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       Statistical significance was determined by 2-tailed Student T tests.  
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Table 1. PCR primers 
 
RASGRP1 FD 
 
GTCTGAGTTGGTACTGTTCCT 
RASGRP1 RV 
 
GGTGAGTCACTCCACAGAGA 
BIM FD 
 
AGTGGGTATTTCTCTTTTGACACA  
BIM RV 
 
TCAATGCCTTCTCCATACCAGACG-3 
HPRT FD 
 
TTGCTGGTGAAAAGGACCTCTCGA 
HPRT RV 
 
CCACAGGACTAGAACACCTGCTAA 
CHIP RASGRP1 CR1 FD 
 
GGACTTCTGTGAAGATACCTCA 
CHIP RASGRP1 CR1 RV 
 
CTCTCTGCACATTGTCATCTGCA 
CHIP RASGRP1 CR2 FD 
 
CTTACAGAGCCAGCAACTTGACTT 
CHIP RASGRP1 CR2 RV 
 
CTCGCATGTCTAGTACATGGACA 
CHIP RASGRP1 CR3 FD 
 
ACAGAGCCAGCAACTTGACTT 
CHIP RASGRP1 CR3 RV 
 
CATGGACAGTAACCAAGGCAGCAA 
CHIP RASGRP1 CR4 FD 
 
CAGGCAGAGCTCAGTCTGGGCCA 
CHIP RASGRP1 CR4 RV 
 
GTGCCAGCAGACCTGGCCAAGA 
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CHAPTER THREE 
EXPERIMENTAL RESULTS 
 
Proximal T cell receptor (TCR) signaling in CD4+CD25+Treg cells and CD4+CD25-T cells 
       Since CD4+CD25+ Treg cells but not non-Treg cells (CD4+CD25- T cells) survive 
PICA inducing conditions, it is expected that CD4+CD25+ Treg cells respond to plate-
bound anti-CD3/anti-CD28 antibody stimulation differently compared to non-Treg cells. In 
plate-bound anti-CD3/anti-CD28 antibody stimulation, immobilized (plate-bound) anti-
CD3 antibody activates TCR signaling and immobilized anti-CD28 antibody activates 
CD28 costimulatory signaling. Although CD28 costimulatory signaling is required for full 
activation of T cells, the main T cell activation signaling is mediated through TCR. 
Therefore, we hypothesized that proximal TCR signaling might be altered in CD4+CD25+ 
Treg cells, thus becoming resistant to PICA. To study TCR signaling in CD4+CD25+ Treg 
cells, we decided to take a biochemical approach. It has been challenging to obtain enough 
Treg cells to perform signaling studies for two reasons. First, CD4+CD25+ Treg cells are 
madeup only 5-10% of CD4+ T cells in humans and mice. Second, commonly used bead-
bound anti-CD3/anti-CD28 antibody stimulation or irradiated antigen presenting cells 
(APC) with anti-CD3 stimulation have difficulties expanding pure populations of 
CD4+CD25+ Treg cells, because a small number of contaminated non-Treg cells can expand 
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Fig. 1 Western blot analysis of Foxp3 expression in ex vivo expanded CD4+CD25+ 
Treg cells and non-Treg cells.  CD4+CD25+ Treg cells or CD4+CD25- T cells were 
isolated from the spleen of BALB/c mice.  CD4+CD25+ Treg cells were stimulated and 
expanded with plate-bound anti-CD3/anti-CD28 antibodies in the presence of IL-2. 
CD4+CD25- T cells were stimulated with bead-bound anti-CD3/anti-CD28 antibodies in 
the presence of IL-2. Cells were harvested at day 7 and rested for overnight without anti-
CD3/ anti-CD28 antibody stimulation. Cells were then directly lysed into SDS sample 
buffer and subjected for western blot analysis using anti-Foxp3 and anti-β actin (for 
loading control) antibodies 
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Fig. 2 Western blot analysis of proximal TCR signaling molecules in in ex vivo 
expanded CD4+CD25+ Tregs and non-Tregs (CD4+CD25- T cells) upon TCR 
activation.  Ex vivo expanded CD4+CD25+ Tregs or non-Tregs (CD4+CD25- T cells) 
isolated from the spleen of BALB/c mice were stimulated with biotin-conjugated anti-
CD3 crosslinked with avidin for 15, 30 min. Cells were then directly lysed into SDS 
sample buffer and subjected for western blot analysis using anti-phospho-LCK (tyrosine 
394), anto-phospho-LCK (tyrosine 505), anti-LCK, anti-TCRζ (A), and phopho-tyrosine 
(B) antibodies. Phosphotyrosine levels of some proteins indicated with arrows were 
downregulated in Treg cells compared to non-Treg cells. In contrast, bands indicated with 
asterisks were detected at higher levels in Treg cells. 
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faster than Treg cells and take over the culture.  Hence, until now, proximal TCR 
signaling in Treg cells has not been well understood. We discovered the phenomenon that 
Treg cells can expand more than 7,000 fold under plate-bound anti-CD3/ anti-CD28 
antibody stimulation while non-Treg cells undergo massive apoptosis. By taking advantage 
of this plate-bound anti-CD3/anti-CD28 antibody stimulation system, we expanded 
electronically sorted CD4+CD25+ Treg cells for 7 days and examined TCR signaling. Since 
non-Treg cells (CD4+CD25- T cells) undergo apoptosis under plate-bound anti-CD3/anti-
CD28 antibody stimulation, we expanded non-Treg cells with bead-bound anti-CD3/anti-
CD28 antibody stimulation for 7 days as a control. After 7 days, both Treg cells and non-
Treg cells were removed from stimulations and rested overnight to examine short term 
TCR stimulation effect in Treg cells. First, we examined Foxp3 expression levels in ex vivo 
expanded Treg cells by western blot. Expanded Treg cells expressed high levels of Foxp3 
while non-Treg cells had very low levels of Foxp3, suggesting that Foxp3+ Treg cells were 
successfully expanded (Fig. 1). Although expanded CD4+CD25- T cells also showed a faint 
Foxp3 band, this could be a small contamination of Foxp3+ Treg cells.  Previously, we 
reported that the amount of Foxp3+ Treg cells was over 95% after 7 days of plate-bound 
anti-CD3/anti-CD28 antibody stimulation using flow cytometry analysis (Singh et al., 
2010). 
        To determine if proximal TCR signaling is altered in Treg cells compared to non-Treg 
cells, ex vivo expanded CD4+CD25+ Treg cells or non-Treg cells (CD4+CD25- T cells) were 
stimulated with biotinylated anti-CD3 antibody cross-linked with avidin. Cells were then 
harvested for western blot after 15 or 30 min of stimulation. The signaling events following 
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TCR activation are depicted by the activation of kinases and phosphorylation of 
tyrosine residues. First, TCR activation leads to phosphorylation of the Src family tyrosine 
kinase, LCK, followed by phosphorylation of immunoreceptor tyrosine-based activation 
motifs (ITAMs) on the TCRζ chain. ZAP70 then binds to phosphorylated ITAMs on the 
TCRζ chain leading to the activation of downstream signaling (Iwashima et al., 1994; 
Straus et al., 1996). Therefore, we determined activation and expression levels of these 
molecules in Treg cells compared to non-Treg cells. Treg cells expressed comparable 
amounts of LCK compared to non-Treg cells and phosphorylation level of LCK residue 
394, 505 stayed at basal levels even after stimulation in both Treg cells and non-Treg cells 
(Fig. 2A).  In contrast, TCRζ   expression was substantially reduced in Treg cells compared 
to non-Treg cells (Fig. 2A). Total phosphotyrosine levels were also altered in Treg cells 
(Fig. 2B).  Phosphotyrosine levels of some proteins indicated with arrows were 
downregulated in Treg cells compred to non-Treg cells. In contrast, bands indicated with 
asterisks were detected at higher levels in Treg cells compared to non-Treg cells. These 
data suggest that proximal TCR signaling in Treg cells is mediated differently compared to 
non-Tregs. 
       Next, we next focused on the downstream signaling cascade of Zap70 and assessed 
activation of the major signaling pathways downstream of TCR signaling, the ??????? 
???????. Surprisingly phosphorylation of Erk was significantly reduced in Tregs and 
barely detectable while non-Treg cells showed strong activation of Erk after 15 or 30min 
after TCR stimulation (Fig. 3A). Further, upstream of the Erk signaling cascade, Mek and 
cRaf, also showed substantially reduced levels of phosphorylation while total protein  
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Fig. 3 Western blot analysis of proximal TCR signaling, Ras-Erk pathway in ex 
vivo expanded CD4+CD25+ Treg cells and non-Treg cells (CD4+CD25- T cells) upon 
TCR activation.  Ex vivo expanded CD4+CD25+ Treg cells or non-Treg cells 
(CD4+CD25- T cells) isolated from the spleen of BALB/c mice were stimulated with 
biotin-conjugated anti-CD3 crosslinked with avidin for 15, 30 min. Cells were then 
directly lysed into SDS sample buffer and subjected for western blot analysis using anti-
phopho-Erk, anti-Erk, anti-phospho-Mek, anti-Mek, anti-phospho-cRaf, anti-cRaf (A), 
anti-Ras, anti-RasGRP1 and SOS (B) antibodies.  
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expression was comparable in Treg cells compared to non-Treg cells (Fig. 3A). These 
data suggest Ras-Erk signaling activity in response to TCR stimulation is substantially 
blocked in Treg cells compared to non-Treg cells though Ras expression was equal between 
Treg cells and non-Treg cells. 
        In T cells, Ras activity is controlled by two Ras activators, RasGRP and SOS. Since 
Ras-Erk pathway is significantly blocked in Treg cells, expression of Ras activators might 
be altered in Treg cells. We then sought to determine the expression of RasGRP1 and SOS 
in Treg cells compared to non-Treg cells.  As we expected, RasGRP1 expression was 
substantially reduced in Treg cells compared to non-Treg cells (Fig 3B).  SOS expression 
was also slightly reduced in Treg cells. These data suggest that the blockade of Erk 
signaling might be due to reduced expression of RasGRP1 and SOS. 
       Next, we next monitored the mobilization of intracellular calcium in Treg cells.  
Calcium signaling is another major proximal TCR signaling pathway. LAT, which is a 
substrate of ZAP70, recruits and activates phospholipaseC γ (PLC γ) (Nishibe et al., 1990).  
PLC γ then leads to the production of IP3 leading to the mobilization of intracellular 
calcium (Crabtree, 1999). In non-Treg cells (CD4+CD25- T cells), phosphorylation of PLCγ 
increased in response to TCR stimulation. In contrast, Tregs showed higher basal level of 
PLCγ activation compared to non-Treg cells. Interstingly, the level of 
PLCγ phosphorylation decreased after TCR stimulation in Treg cells. The total expression 
of PLCγ was comparable between Treg cells and non-Treg cells (Fig 4A).  
       We then assessed calcium levels in response to TCR stimulation in Treg cells 
compared to non-Treg cells. As described above, Treg cells and non-Treg cells were  
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Fig. 4 Calcium signaling in in ex vivo expanded CD4+CD25+ Treg cells and non-
Treg cells (CD4+CD25- T cells) upon TCR activation.   (A) Ex vivo expanded 
CD4+CD25+ Treg cells or non-Treg cells (CD4+CD25- T cells) isolated from the spleen of 
BALB/c mice were stimulated with biotin-conjugated anti-CD3 cross-linked with avidin 
for 15, 30 min. Cells were then directly lysed into SDS sample buffer and subjected for 
western blot analysis using anti-phospho-PLC γ and anti-PLC γ antibodies. (B) Ex vivo 
expanded CD4+CD25+ Treg cells or non-Treg cells (CD4+CD25- T cells) isolated from the 
spleen of C57BL/6 mice were laoded with Fura2-AM and stimulated with biotin-
conjugated anti-CD3 cross-linked with avidin. Intracellular calcium level was determined 
by the ratio between emission fluorescence intensities at 340nm and 380nm.  
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expanded and rested overnight. Cells loaded Fura-2-AM were stimulated with avidin 
crosslinked anti-CD3 and calcium mobilization in these cells was assessed. In response to 
TCR stimulation, the elevation of intracellular calcium concentration, [Ca2+] was observed 
in both Treg cells and non-Treg cells. However, the [Ca2+] in Treg cells reached to a much 
lower peak compared to non-Treg cells and declined to basal level. These data suggest that 
calcium signaling is also altered in Treg cells. Altogether, data above indicate that proximal 
TCR signaling is highly impaired in Treg cells compared to non-Treg cells. 
 
Lack of RasGRP1 expression rescues non-Treg cells from PICA 
        We have demonstrated that proximal TCR signaling is drastically altered in 
CD4+CD25+ Treg cells compared to non-Treg cells (CD4+ CD25- T cells).  This difference 
may be the key that renders Treg cells resistant to PICA and the reason why the same 
plate-bound anti-CD3/CD28 antibody stimulation leads to different outcomes for 
CD4+CD25+ Treg cells and non-Treg cells (CD4+CD25- T cells), either survival or death.  
The most drastic differences in CD4+CD25+Treg cells were downregulation of RasGRP1 
and the blockade of its down stream Ras-Erk activity in response to TCR stimulation. 
RasGRP1 transmits the TCR activation signal to Ras by converting the Ras-GDP bound 
form to the active Ras-GTP binding form.  Whereas there are two Ras activators in T 
cells, SOS and RasGRP1, Roose et al. demonstrated that RasGRP1 dominantly controls 
Erk activation in response to TCR stimulation (Roose et al., 2005).  Further, Dower et al. 
showed that TCR dependent Erk activation is impaired in RasGRP1 deficient thymocytes 
(Dower et al., 2000). Hence, it is expected that the Ras-Erk pathway is unresponsive 
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during TCR activation in Treg cells because of the downregulation of RasGRP1.  Ras-
Erk signaling is highly conserved among vertebrates and plays crucial roles in 
determining cellular physiology such as cell survival, proliferation and differentiation 
(Ramos, 2008). In the case of T cells, Erk signaling plays an important role in thymic 
positive and negative selection (Bommhardt et al., 2000; Daniels et al., 2006; 
Mariathasan et al., 2001; Werlen et al., 2003). Whereas it is well studied that Erk 
activation is important for cell survival, Martin et al. reported that sustained Erk signaling 
promotes cell death using multiple cell types including the human lymphoblastoid Boleth 
cell line (Martin et al., 2006).  Therefore, we focused on RasGRP1 expression in 
CD4+CD25+ Treg cells and non-Treg cells (CD4+CD25- T cells) and its down stream 
Ras/Erk pathway. We hypothesized that the downregulation of RasGRP1 expression in 
CD4+CD25+ Treg cells might be important for cell survival under PICA inducing 
condition, plate-bound anti-CD3/anti-CD28 antibody stimulation. In other words, 
CD4+CD25- T cells might undergo apoptosis in a RasGRP1/ Ras/ Erk signaling dependent 
manner under PICA inducing conditions. To test our hypothesis, we used RasGRP1 
knockout mice, which exhibit abnormal T cell development in the thymus due to 
impaired positive selection (Dower et al., 2000). These mice develop autoimmune 
disorders. These mice exhibit splenomegaly and enlarged spleens contain higher number 
of CD4+ T cells whereas fewer numbers of CD4+CD25+ Treg cells in the periphery (Chen 
et al., 2008). The rationale of this experiment is if the downregulation of RasGRP1 is 
important for CD4+CD25+ Treg cell survival under plate-bound anti-CD3/atni-CD28 
antibody stimulation, then RasGRP1 deficient CD4+CD25- T cells would also become  
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Fig. 5 The lack of RasGRP1 expression rescues non-Tregs from PICA.   CD4+CD25- 
T cells isolated from the spleen of RasGRP1 knockout mice (RasGRP-/-) or littermate 
control (Wt) were stimulated with anti-CD3/anti-CD28 antibodies. Cells were harvested 
at day 4. (A) Total number of live cells was determined. (B) Cells were stained with 
annexin V and analyzed by flow cytometry. 
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Fig. 6 Effect of RasGRP1 expression on Erk activity by CD4+CD25- T cells under 
plate-bound anti-CD3/anti-CD28 antibody stimulation.  CD4+CD25- T cells isolated 
from the spleen of RasGRP1 knockout mice (KO) or littermate control (WT) were 
stimulated with plate-bound anti-CD3/anti-CD28 antibodies supplemented with IL-2. 
Cells were harvested at day 3. Cells were lysed into SDS sample buffer and subjected for 
western blot analysis using anti-phopho-Erk, anti-Erk and anti-β actin (for loading 
control) antibodies. 
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resistant to PICA as wild type CD4+CD25+ Tregs do. To address this question, we 
cultured electronically sorted CD4+CD25- T cells isolated from the spleen of RasGRP1 
knockout mice or littermate control with plate-bound anti-CD3/anti-CD28 antibody 
stimulation. After 4 days of stimulation, cells were harvested and cell viability was 
assessed by flow cytometry analysis. As expected, cells isolated from wild type 
littermates underwent massive apoptosis and over 80% of the cells became annexinV+ 
(Fig. 5A). In contrast, RasGRP1 deficient cells isolated from the spleen of RasGRP1 
knockout mice showed a substantial decrease in the percentage of annexinV+ cells (37%) 
(Fig. 5A). The total live cell number of wild type CD4+CD25- T cells decreased 30 fold  
from day 0 (Fig. 5B). In contrast, the total live cell number of RasGRP1 deficient 
CD4+CD25- T cells increased 4 fold from day 0. These data suggest that non-Treg cells  
 (CD4+CD25- T cells), which lack RasGRP1 expression avoid apoptosis and expand under 
PICA inducing condition with plate-bound anti-CD3/anti-CD28 antibodies.  We then 
determined whether Erk activation is impaired in RasGRP1 deficient CD4+CD25- T cells 
under PICA inducing condition. To address this question, we cultured electronically 
sorted CD4+CD25- T cells isolated from the spleen of RasGRP1 knockout mice or 
littermate control mice with plate-bound anti-CD3/anti-CD28 antibody stimulation. After 
3 days of culturing, cells were harvested and lysed in SDS sample buffer. Erk activation, 
determined by levels of phosphorylated Erk, was assessed by western blot analysis. 
Phosphorylation of Erk was observed from wild type cells, but Erk activation was barely 
detectable from RasGRP1 deficient cells, suggesting that RasGRP1 deficient cells 
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exhibited impaired Erk activity in response to plate-bound anti-CD3/ anti-CD28 
antibody stimulation (Fig. 6).  
 
Lack of RasGRP1 expression downregulates Bim expression 
     It is now clear that the lack of RasGRP1 expression renders CD4+ T cells resistant to 
apoptosis and its downstream Erk activity is impaired in the absence of RasGRP1 under 
PICA inducing condition. We next sought to determine how lack of RasGRP1 expression 
changes the fate of non-Tregs from death to survival under PICA inducing stimuli. T cell 
apoptosis is mainly mediated by two different pathways, Fas and Bim (Hutcheson et al., 
2008). Fas belongs to the death receptor, Tumor necrosis factor (TNF) receptor family. The 
Fas/Fas ligand interaction induces activation of caspase 8 through the formation of the 
death inducing signaling complex (Kischkel et al., 1995). Cell surface expression of Fas is 
highly upregulated upon TCR stimulation. Bim belongs to the Bcl-2 family and initiates 
apoptosis via the intrinsic pathway by activating caspase 9. Both Fas and Bim are crutial for 
maintaining cell homeostasis. We previously reported that CD4+CD25- T cells isolated 
from Bim knockout mice or lpr mice which lack functional Fas ligand are resistant to PICA 
and are able to survive and expand under plate-bound anti-CD3/anti-CD28 antibody 
stimulation (Singh et al., 2010). These data indicate that PICA is induced in a both Bim and 
Fas/FasL dependent manner. Further, the cell surface expression of FasL/Fas and Bim were 
substantially upregulated when non-Treg cells were stimulated with plate-bound anti-
CD3/anti-CD28 antibodies. In contrast, Treg cells did not exhibit increased expression of 
those proapoptotic proteins and kept basal level of Bim and Fas ligand cell surface  
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Fig. 7 Effect of RasGRP1 expression on apoptotic protein expression by CD4+CD25- 
T cells under plate-bound anti-CD3/anti-CD28 antibody stimulation.   CD4+CD25- T 
cells isolated from the spleen of RasGRP1 knockout mice (KO) or littermate control 
(WT) were stimulated with plate-bound anti-CD3/anti-CD28 antibodies. Cells were lysed 
in SDS sample buffer at day 3 and subjected for western blot analysis using anti-Bim, 
anti-Fas ligand and anti-β actin (for loading control) antibodies. EL and L forms of Bim 
are indicated with arrowheads. Membrane-bound and soluble forms of Fas ligand are 
indicated with arrowheads. 
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expression under plate-bound anti-CD3/anti-CD28 antibody stimulation. To determine 
if the lack of RasGRP1 expression in CD4+CD25- T cells blocks upregulation of Bim and 
Fas/ FasL, we cultured electronically sorted CD4+CD25- T cells isolated from the spleen of 
RasGRP1 knockout mice or littermate control under plate-bound anti-CD3/anti-CD28 
antibody stimulation. After 3 days, cells were harvested and lysed in SDS sample buffer. 
Bim, Fas and Fas ligand expression were assessed by western blot analysis. At day 3, wild 
type cells exhibited increased Bim expression compared to unstimulated cells. In contrast, 
RasGRP1 deficient cells expressed basal levels of Bim after stimulation (Fig. 7A). 
Unstimulated cells also showed lower Bim expression compared to wild type cells. Fas 
ligand expression was increased in both RasGRP1 knockout cells and wild type cells, 
suggesting there is no effect of RasGRP1 on FasL expression (Fig. 7B). These data suggest 
that upregulation of Bim under plate-bound anti-CD3/anti-CD28 antibody stimulation is in 
a RasGRP1 expression dependent manner.  
 
Regulation of RasGRP1 expression in CD4+ T cells 
       The data above indicate that the level of RasGRP1 expression correlates with CD4+ T 
cell fate of death or survival. As described in Fig. 3B, we demonstrated that Treg cells 
substantially downregulate RasGRP1 expression compared to non-Treg cells. This 
experiment was done using ex vivo-expanded cells to obtain enough CD4+CD25+ Treg cells 
for western blot analysis. Since it is not understood how the rasgrp1 gene is regulated in 
response to TCR stimulation, we next compared the RasGRP1 expression levels in freshly 
isolated cells and activated state of CD4+CD25+ Treg cells/ CD4+CD25- T cells.  
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Fig. 8 Western blot analysis of RasGRP1 expression on CD4+CD25+ Treg cells and 
CD4+CD25- T cells.  CD4+CD25+ Treg cells or CD4+CD25- T cells were isolated from 
the spleen of BALB/c mice.  CD4+CD25+ Treg cells were stimulated and expanded with 
plate-bound anti-CD3/anti-CD28 antibodies in the presence of IL-2. CD4+CD25- T cells 
were stimulated with bead-bound anti-CD3/anti-CD28 antibodies in the presence of IL-2. 
Cells were harvested at day 0 or day 7. Cells were then lysed into SDS sample buffer and 
subjected for western blot analysis using anti-RasGRP1 and anti-β actin (for loading 
control) antibodies. 
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Fig. 9 The rasgrp1 gene expression in CD4+CD25+ Treg cells and CD4+CD25- T cells.  
CD4+CD25+ Treg cells or CD4+CD25- T cells were isolated from the spleen of BALB/c 
mice.  CD4+CD25+ Treg cells were stimulated and expanded with plate-bound anti-
CD3/anti-CD28 antibodies in the presence of IL-2. CD4+CD25- T cells were stimulated 
with bead-bound anti-CD3/anti-CD28 antibodies in the presence of IL-2. Cells were 
harvested at day 7 and total RNA was isolated for real time PCR. * p<0.05 
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Electronically sorted CD4+CD25+ Treg cells were stimulated with plate-bound anti-
CD3/CD28 antibodies. FACS sorted CD4+CD25- T cells were stimulated with bead-bound 
anti-CD3/anti-CD28 antibodies. Cells were harvested at day 0 and day 7 and lysed in SDS 
sample buffer. RasGRP1 expression was assessed by western blot analysis. If RasGRP1 
expression changes in response to TCR stimulation, then we would expect to see different 
expression patterns from freshly isolated cells compared to activated cells. Surprisingly, 
both CD4+CD25+ Treg cells and non-Treg cells (CD4+CD25- T cells) expressed comparable 
levels of RasGRP1 at day 0 (unstimulated) (Fig. 8A). After 7 days of in vitro stimulation, 
non-Treg cells showed a substantial increase of RasGRP1 expression from basal level, 
while CD4+CD25+ Treg cells slightly downregulated RasGRP1 expression. These data 
indicate that large differences of RasGRP1 expression previously observed between 
CD4+CD25+ Treg cells and non-Treg cells was due to upregulation of RasGRP1 in non-
Treg cells in response to TCR stimulation, since freshly isolated cells (unstimulated cells) 
showed basal levels of RasGRP1 expression in both Treg cells and non-Treg cells. To 
determine if reduced expression of RasGRP1 in Treg cells is regulated at the transcriptional 
level, we isolated RNA from in vitro expanded CD4+CD25+ Treg cells or CD4+CD25- T 
cells and performed quantitative PCR (Fig. 9). At day 7, non-Treg cells expressed higher 
amount of rasgrp1 compared to Treg cells, suggesting that reduced RasGRP1 expression in 
Treg cells is mediated by transcriptional regulation. 
      CD4+CD25- T cells can be differentiated into Foxp3+ Treg cells (inducible Treg cells) in 
the periphery when TGF-β is present (Chen et al., 2003; Wan and Flavell, 2005). Next, we 
determined if inducible Tregs also downregulate RasGRP1 expression under TCR  
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Fig. 10 RasGRP1 expression by CD4+CD25- T cells in iTreg cell polarizing 
condition.  CD4+CD25- T cells isolated from the spleen of C57BL/6 mice were 
stimulated with plate-bound anti-CD3 and soluble anti-CD28 antibodies. Cells were 
harvested at day 0, 1, 3, 4 and 7. Cells were lysed into SDS sample buffer and subjected 
for western blot analysis using anti-RasGRP1, anti-Foxp3 and anti-β actin antibodies. 
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stimulation. To address this question, electronically sorted CD4+CD25- T cells were 
stimulated with plate-bound anti-CD3 plus soluble anti-CD28 antibodies in the presence or 
absence of TGF-β. Stimulation with plate-bound anti-CD3 plus soluble anti-CD28 in the 
presence of TGF-β has previously been in reported as iTreg cell polarizing conditions 
(Fantini et al., 2007). After 1, 3, 5 or 7 days of culturing, cells were lysed in SDS sample 
buffer. RasGRP1 expression and Foxp3 expression were assessed by western blot analysis. 
In the absence of TGF-β, no Foxp3 induction occurred while RasGRP1 expression 
gradually increased with the highest peak observed at day 7 (Fig. 10). In contrast, cells 
stimulated in the presence of TGF-β started to express Foxp3 after one day of stimulation 
and gradually increased its expression level with longer activation, suggesting that cells 
differentiated into iTreg cells. Although increased expression of Foxp3 expression is either 
due to an increase of Foxp3 expression per cell or an increase in the proportion of Foxp3+ T 
cells, RasGRP1 expression was inversely correlated to Foxp3 expression and was reduced 
from basal level. As Foxp3 expression increased, RasGRP1 expression reduced in the 
presence of TGF-β suggesting that iTreg cells also downregulated expression of RasGRP1.  
 
Foxp3 directly associate with rasgrp1 gene 
       We next determined by which mechanism CD4+CD25+ Treg cells downregulate 
RasGRP1 expression. As we described in Fig. 9, downregulation of rasgrp1 is mediated at 
the transcriptional level. Further, we showed that RasGRP1 expression was reciprocally 
correlated with Foxp3 expression in the iTreg cell induction model (Fig. 10). Foxp3 is a 
transcription factor recognized as the most descriptive marker of Tregs and expressed by  
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Fig. 11 Foxp3 interaction with rasgrp1 gene in CD4+CD25+ Treg cells.   (A) 
Forkhead consensus sequences were found in rasgrp1 promoter region indicated with red 
ellipses. CR1, 2, 3, 4 and 5 are regions amplified by PCR. (B) Expanded CD4+CD25+ 
Treg cells isolated from the spleen of C57BL/6 mice were lysed and cross-linked for 
ChIP assay. DNA was extracted from precipitated samples for PCR primer sets which 
amplify forkhead consensus regions from rasgrp1 promoter. 
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both nTreg cells and iTreg cells in mice. Foxp3 negatively or positively controls many 
genes which are related to Treg functions. Overexpression of Foxp3 is sufficient to make T 
cells suppressive function (Hori et al., 2003). Therefore, we hypothesized that Foxp3 might 
downregulate rasgrp1 expression by directly associating with the rasgrp1 transcription 
control region.  To address this question, we determined if Foxp3 associates with the 
transcription control region of rasgrp1. Foxp3 belongs to the fork head family that binds to 
fork head consensus TRTTKW as previously reported (Overdier et al., 1994). Therefore, 
we first searched if there are any forkhead consensus sequences upstream of rasgrp1 from 
the transcription starting site. We found that there are 4 potential Foxp3 binding sites up to 
4 kb upstream of the rasgrp1 gene (Fig. 11A). To determine if Foxp3 binds to these 
forkhead consensuses which exist upstream of the rasgrp1 transcription starting site, we 
designed the primers to amplify these regions and performed a ChIP assay. Expanded Treg 
cells were lysed and cross-linked. Cell lysates were precipitated using anti-Foxp3 antibody 
or an isotype control antibody. If Foxp3 binds to upstream of the rasgrp1 transcription 
starting site, we would expect to see that DNA fragment precipitated with Foxp3 and 
amplified by PCR reaction. Among the Foxp3 antibody precipitated samples, only the CR1 
and CR2 primer sets amplified clearly detectable bands (Fig. 11B). Since no bands were 
detected from isotype precipitated samples, these data suggest that Foxp3 directly 
associates with the rasgrp1 gene and possibly downregulates rasgrp1 transcription in Treg 
cells.  
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TGF-β signaling in CD4+ T cells and PICA 
  The data above focused on the difference of proximal TCR signaling between 
CD4+CD25+ Treg cells and other non-Treg cells (CD4+CD25- T cells) and found that Ras 
guanyl nucleotide exchange protein 1 (RasGRP1) is downregulated in CD4+CD25+ Treg 
cells compared to other CD4+ T cells. Further, we showed RasGRP1 expression in non-
Treg cells (CD4+CD25- T cells) is critical to promote apoptosis under PICA inducing 
condition stimulated with plate-bound anti-CD3/ anti-CD28 antibody. Altogether, these 
data indicate that downregulation of RasGRP1 in CD4+CD25+ Treg cells might be one of 
the survival mechanisms against apoptosis under plate-bound anti-CD3/anti-CD28 
antibody stimulation.  
       Is downregulation of RasGRP1 in CD4+CD25+ Treg cells the only mechanism to 
control cell survival? Next, we focused on the downstream events of proximal TCR 
signaling, which includes cytokine production. CD4+ T cells produce a variety of 
cytokines such as IL-2, IL-4 and IFN-γ in response to TCR stimulation along with CD28 
co-stimulation. TGF-β is a pleiotropic cytokine, which is also produced by CD4+ T cells 
and influences cell proliferation, apoptosis and differentiation (Chang et al., 2003; 
Conery et al., 2004; Jung et al., 2004; Murillo et al., 2005; Sillett et al., 2001). TGF-β is 
secreted in an inactive form by noncovalently attaching to latency associated peptide 
(LAP) (Li and Flavell, 2008). Nakamura et al. reported that CD4+CD25+ Treg cells 
produce more TGF-β compared to other CD4+ effector T cells (Nakamura et al., 2001). 
Furthermore, CD4+CD25+ Treg cells but not other CD4+ effector T cells (CD4+CD25- T 
cells) express TGF-β on their surface by interacting with LAP and anchor protein, GARP  
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Fig. 12 Effect on TGF-β  signaling blockade on PICA of CD4+CD25+ Treg cells. 
CD4+CD25+ Treg cells isolated from the spleen of C57BL/6 mice were stimulated with 
plate-bound anti-CD3/anti-CD28 antibodies in the presence or absence of SB431542 
(TGF-β super-family type I receptor kinase inhibitor) or anti-TGF-β antibody in media 
supplemented with IL-2. (A) Cells were harvested at day 3 and total number of live cells 
was determined. (B) At day 3, cells were stained with annexin V and analyzed by flow 
cytometry. ** p< 0.01 
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(Glycoprotein A repetitions predominant) (Tran et al., 2009). Surface bound TGF-β on 
CD4+CD25+ Treg cells exerts a suppressive function toward effector T cells (Nakamura 
et al., 2001). Although it is not well understood if there are any other specific roles of 
surface bound TGF-β, there are clear differences about TGF-β production and its 
expression style between CD4+CD25+ Treg cells and other CD4+ effector T cells. Hence 
we hypothesized that there is more active TGF-β signaling in Treg cells and that might be 
important for CD4+CD25+ Treg cell survival under PICA inducing condition, plate-bound 
anti-CD3/anti-CD28 antibody stimulation. To test our hypothesis, we first determined if 
TGF-β  signaling is required for the survival of Treg cells. To inhibit TGF-β signaling in 
Treg cells, we used a TGF-β super-family type I receptor kinase inhibitor (SB431542) or 
a TGF-β neutralizing antibody.  SB431542 is a small molecule inhibitor that blocks TGF-
β type I receptor serine/threonine kinase activity by competing with the ATP binding site 
of its kinase. TGF-β neutralizing antibody binds to TGF-β thus blocking TGF-β 
association with the TGF-β receptor. Purified CD4+CD25+ Treg cells were stimulated 
with plate-bound anti-CD3/anti-CD28 antibodies in the presence of TGF-β signaling 
inhibitor (SB431542) or anti-TGF-β neutralizing antibody (anti-TGF-β-1, 2, 3 antibody). 
If TGF-β signaling is important for CD4+CD25+ Treg cell survival, we would expect to 
see that CD4+CD25+ Treg cells inhibited TGF-β signaling would undergo apoptosis under 
plate-bound anti-CD3/anti-CD28 antibody stimulation. After three days of stimulation, 
cells were harvested and analyzed by flow cytometry.  CD4+CD25+ Treg cells expanded  
~2 fold compared to the starting cell number (Fig. 12A).  When TGF-β super-family type  
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Fig. 13 Effect of TGF-β  signaling blockade on PICA of CD4+CD25+ Treg cells. 
CD4+CD25+ Treg cells isolated from the spleen of dnTgfbr2mice or wildtype littermate 
control were stimulated with plate-bound anti-CD3/anti-CD28 antibodies. (A) Cells were 
harvested at day 3 and total number of live cells was determined. (B) At day 3, cells were 
stained with annexin V and analyzed by flow cytometry. **p< 0.01 
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I receptor kinase inhibitor (SB431542) was added, cell growth was substantially 
blocked and the cell number decreased approximately 5 fold.  Similarly, when 
CD4+CD25+ Treg cells were treated with anti-TGF-β antibody, live cell number 
decreased substantially compared to the starting number (Fig. 12A).  Flow cytometric 
analysis showed that this decrease in cell numbers corresponds to an increase in annexin 
V+ apoptotic/dead cell frequency (Fig. 12B).  These data suggest that TGF-β signaling in 
CD4+CD25+ Tregs is critical for cell survival under PICA inducing condition, stimulation 
with plate-bound anti-CD3/ anti-CD28 antibodies.  
To further confirm these results, we examined PICA resistance by CD4+CD25+ Treg 
cells isolated from transgenic mice expressing a dominant-negative form of TGF-β receptor 
type II under the control of mouse CD4 promoter (CD4dnTgfbr2).  These mice have a 
normal level of Foxp3+CD4+CD25+ Treg cells (~8 weeks old) although TGF-β receptor 
signaling is substantially blocked in T cells.  We isolated splenic CD4+CD25+ Treg cells 
from CD4dnTgfbr2 mice or their wild type littermate control and stimulated them with 
plate-bound anti-CD3/anti-CD28 antibodies in the presence of IL-2.  After 3 days of 
culture, we harvested cells and assessed their survival (Fig. 13A).  While the number of 
wild type littermate Treg cells increased from day 0, the number of CD4dnTgfbr2 Treg cells 
was less than 10% of the control and decreased compared to the starting cell number.  As 
observed with the chemical inhibitor of TGF-β signaling and TGF-β neutralizing antibody, 
the frequency of annexinV+ cells were about 2 fold higher in CD4dnTgfbr2 T cell culture 
compared to that of the littermate control (Fig. 13B).  Since we did not add exogenous 
TGF-β to the culture, the data strongly suggest that CD4+CD25+ Treg cells provide TGF- 
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Fig. 14 Effect of TGF-β  on PICA by CD4+CD25- T cells.   CD4+CD25- T cells isolated 
from the spleen of C57BL/6 mice were stimulated with plate-bound anti-CD3/anti-CD28 
antibodies in the presence or absence of recombinant TGF-β in media supplemented with 
IL-2. (A) Cells were harvested at day 3 and stained with annexin V for flow cytometry 
analysis. (B) Total number of live cells was determined at day 3. **p< 0.01 
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β in an autocrine manner to maintain CD4+CD25+ Treg cell resistance against PICA.  
 
Exogenous TGF-β renders CD4+CD25- T cells resistant to PICA 
       Since TGF-β signaling is important for the survival of CD4+CD25+ Treg cells in an 
autocrine manner, it is possible that non-Tregs (CD4+CD25- T cells) undergo apoptosis 
????? plate-bound anti-CD3/anti-CD28 antibody stimulation due to less or lack of TGF-
β signaling. Ouyang et al. reported that CD4+CD25- T cells express comparable level of 
TGF-β receptor although it is slightly lower than Treg cells (Ouyang et al., 2010). Since the 
TGF-β receptor is expressed in non-Tregs (CD4+CD25- T cells), the addition of the active 
form of TGF-β might might render a survival signal to non-Tregs (CD4+CD25- T cells) 
from PICA under plate-bound anti-CD3/anti-CD28 antibody stimulation. We cultured 
FACS sorted CD4+CD25- T cells under PICA-inducing conditions, stimulation with anti-
CD3/anti-CD28 antibodies, in the presence or absence of exogenous TGF-β.  After 3 days 
of culturing, we harvested cells and assessed their survival.  As observed previously, cells 
that were stimulated by plate-bound anti-CD3/anti-CD28 antibodies underwent apoptotic 
cell death detected by an increase of annexin V+ cells (Fig 14A).  When exogenous TGF-
β was added to the culture, as we predicted, the frequency of apoptotic/dead cells decreased 
substantially.  This change with the addition of TGF-β was due to expansion of the number 
of live cells and not due to a decrease of annexin V+ cell numbers (Fig. 14B).  When 
CD4+CD25- T cells were stimulated with plate-bound anti-CD3/anti-CD28 antibodies, the 
final live cell number after 3 days of stimulation was about the same as the starting sample 
(1.2 fold increase).  In contrast, the annexin V- cell number increased by 2.8 fold when 
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CD4+CD25- T cells were stimulated with plate-bound anti-CD3/anti-CD28 antibodies 
in the presence of TGF-β.  These data show that TGF-β renders CD4+CD25- T cells 
resistant to PICA and allows them to expand. 
 
TGF-β signaling downregulates Bim expression 
        We have demonstrated that CD4+CD25+ Treg cells resist PICA in an autocrine TGF-β 
signaling dependent manner and non-Treg cells (CD4+CD25- T cells) are rescued from 
apoptosis in the presence of TGF-β, suggesting TGF-β signaling is a key to controlling 
CD4+ T cell fate (survival or apoptosis) under PICA inducing conditions. We then sought to 
determine by which mechanisms TGF-β signaling rescues CD4+ T cells from PICA under 
plate-bound anti-CD3/anti-CD28 antibody stimulation. As we described above, T cell 
apoptosis is mainly mediated by two different pathways, Fas and Bim. We previously 
reported that CD4+CD25- T cells isolated from Bim knockout mice or lpr mice which lack 
functional Fas ligand are resistant to PICA and are able to survive and expand under plate-
bound anti-CD3/anti-CD28 antibody stimulation (Singh et al., 2010). These data indicate 
that PICA is induced in both a Bim and Fas/FasL dependent manner. Further, those 
proapoptotic molecules, Bim and Fas ligand (cell surface) expression were substantially 
upregulated when non-Treg cells were stimulated with plate-bound anti-CD3/anti-CD28 
antibody stimulation. In contrast, Treg cells did not exhibit increased expression of those 
proapoptotic proteins and kept basal level of Bim and Fas ligand in the same stimulation 
condition. We therefore hypothesized that TGF-β signaling in CD4+ T cells might 
downregulate these apoptotic proteins. Since TGF-β rescued CD4+CD25- T cells from  
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Fig. 15 Effect of TGF-β  on Bim expression by CD4+CD25- T cells.  CD4+CD25- T cells 
isolated from the spleen of C57BL/6 mice were stimulated with plate-bound anti-
CD3/anti-CD28 antibodies in the presence or absence of recombinant TGF-β in media 
supplemented with IL-2. Cells were harvested at day 3. Cells were lysed into SDS sample 
buffer and subjected for western blot analysis using anti-Bim and anti-β actin (for loading 
control) antibodies. EL and L forms are indicated with arrows.  
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Fig. 16 Effect on TGF-β  signaling on cell surface expression of Fas and FasL by 
CD4+CD25- T cells.  CD4+CD25- T cells isolated from the spleen of C57BL/6 mice were 
stimulated with plate-bound anti-CD3/anti-CD28 antibodies in the presence or absence of 
recombinant TGF-β in media supplemented with IL-2. (A) Cells harvested at day 3 were 
stained for Fas ligand (FasL) expression and analyzed by flow cytometry. (B) Cells 
harvested at day 3 were stained for Fas expression and analyzed by flow cytometry. 
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Fig. 17 Effect of TGF-β  on bim transcript by CD4+CD25- T cells.  CD4+CD25- T cells 
isolated from the spleen of C57BL/6 mice were stimulated with plate-bound anti-
CD3/anti-CD28 antibodies in the presence or absence of recombinant TGF-β in media 
supplemented with IL-2. Cells were harvested at day 3 and total RNA was isolated for 
real time PCR. Bim gene expression was normalized to hprt transcript. 
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PICA under plate-bound anti-CD3/ anti-CD28 antibody stimulation, we first 
determined whether addition of exogenous TGF-β reduces expression of Bim and/or Fas 
ligand by CD4+CD25- T cells. If our hypothesis is correct, we would expect to observe that 
CD4+CD25- T cells cultured in the presence of TGF-β decreases the expression of Bim or 
Fas/Fas ligand. Unstimulated CD4+CD25- T cells expressed two forms (L and EL isoforms) 
of Bim at a basal level. When stimulated with plate-bound anti-CD3/anti-CD28 antibodies, 
CD4+CD25- T cells expressed both forms of Bim at a level clearly higher than that seen in 
unstimulated T cells (Fig 15).  Stimulated CD4+CD25- T cells in the presence of TGF-β, on 
the other hand, showed a markedly reduced level of Bim protein expression, even lower 
than that in unstimulated T cells.  In contrast to Bim expression, TGF-β treatment caused a 
mild reduction in expression of FasL in CD4+CD25- T cells (Fig. 16A), while expression of 
Fas did not differ between TGF-β treated or untreated samples (Fig. 16B).  Together, the 
data clearly show that TGF-β suppresses the expression of molecules required for 
apoptosis, particularly Bim, by CD4+CD25- T cells stimulated by PICA-inducing 
conditions. Bim is regulated at both transcriptional and posttranscriptional regulations 
(Ewings et al., 2007). We then determined if TGF-β reduced the expression of Bim in 
CD4+CD25- T cells at transcriptional level by performing real time PCR. Bim gene 
expression level in TGF-β treated cells were about 3 fold lower compared to untreated cells 
under plate-bound anti-CD3/anti-CD28 antibody stimulation, suggesting that TGF-
β negatively regulates the transcription of bim (Fig 17). 
       We next determined if TGF-β signaling in CD4+CD25+ Treg cells plays the same role 
as in conventional T cells.  If TGF-β signaling in CD4+CD25+ Treg cells keeps cells 
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resistant to PICA, it would be expected that CD4+CD25+ Treg cells treated with TGF-β 
signaling inhibitor (SB431542) would express higher levels of Bim.  To test this, 
CD4+CD25+ Treg cells were purified and stimulated with plate-bound anti-CD3/anti-CD28 
antibodies for 3 days with or without TGF-β signaling inhibitor (SB431542).  Three days 
later, cells were harvested and tested for the expression of Bim, Fas and FasL (cell surface) 
(Fig. 18 and Fig. 19).  Stimulated Treg cells expressed a comparable level of Bim protein to 
unstimulated cells and showed a stark contrast to Bim expression by CD4+CD25- T cells as 
we reported previously.  In contrast, Treg cells that were stimulated in the presence of 
TGF-β signaling inhibitor showed a substantial upregulation of Bim expression (Fig. 18).  
The increase was more evident for the EL form of Bim than for the L form.  The EL form is 
considered to play a major role in apoptosis by inducing the release of apoptotic proteins 
Bax and Bak.  Unlike Bim, Fas and FasL expression by stimulated by CD4+CD25+ Treg 
cells did not increase with TGF-β treatment (Fig. 19A, B). We then determined if TGF-β 
signaling in Treg cells negatively regulate Bim expression at transcriptional level as 
CD4+CD25- T cells. If TGF-β signaling in Treg cells negatively regulates Bim expression 
at transcriptional level, then we would expect to see upregulation of bim transcription in 
TGF-β signaling inhibitor treated Treg cells under plate-bound anti-CD3/anti-CD28 
antibody stimulation.  After 2 days of plate- bound anti-CD3/anti-CD28 antibody 
stimulation in the presence or absence of TGF-β signaling inhibitor, Tregs were harvested 
and total RNA was isolated to perform quantitative PCR. As we expected, bim gene 
expression was 3 fold higher in TGF-β signaling inhibitor (SB431542) treated Treg cells 
compared to DMSO treated control, suggesting that TGF-β signaling in Treg cells also 
  
78 
 
Fig. 18 Effect of TGF-β  signaling on Bim expression by CD4+CD25+ Treg cells.  
CD4+CD25+ Treg cells isolated from the spleen of C57BL/6 mice were stimulated with 
plate-bound anti-CD3/antiCD28 antibodies in the presence or absence of SB431542 
(TGF-β super-family type I receptor kinase inhibitor) in media supplemented with IL-2 
for 2 days. Cells were harvested and lysed in SDS sample buffer and subjected for 
western blot analysis using anti-Bim or anti-β actin (for loading control) antibodies. 
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Fig. 19 Effect of TGF-β  signaling on cell surface expression of Fas and FasL by 
CD4+CD25+ Treg cells. CD4+CD25+ Treg cells isolated from the spleen of C57BL/6 
mice were stimulated with plate-bound anti-CD3/antiCD28 antibodies in the presence or 
absence of SB431542 (TGF-β super-family type I receptor kinase inhibitor) in media 
supplemented with IL-2. (A) Cells harvested at day 2 were stained for Fas ligand (FasL) 
expression and analyzed by flow cytometry. (B) Cells harvested at day 2 were stained for 
Fas expression and analyzed by flow cytometry. 
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Fig. 20 Effect of TGF-β  signaling on bim transcript by CD4+CD25+ Treg cells.  
CD4+CD25+ Treg cells isolated from the spleen of C57BL/6 mice were stimulated with 
plate-bound anti-CD3/anti-CD28 antibodies in the presence or absence of recombinant 
TGF-β in media supplemented with IL-2. Cells were harvested at day 2 and total RNA 
was isolated for real time PCR. Bim gene expression was normalized to hprt transcript. 
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downregulates Bim at transcriptional regulation (Fig. 20). Taken together with the data 
from studies with CD4+CD25- T cells, the data demonstrate that TGF-β signaling plays a 
pivotal role in suppression of the Bim under PICA inducing conditions.  
        
Effect of TGF-β for CD4+ T cell differentiation under PICA inducing conditions 
       As mentioned above, TGF-β signaling also promotes T cell differentiation. It is well 
established that TGF-β can induce differentiation of naïve CD4+ T cells into Foxp3+ 
inducible Treg (iTreg) cells.  Since CD4+CD25+ naturally arising Treg cells are resistant to 
PICA, we then hypothesized that the survival of CD4+CD25- T cells observed with 
exogenous TGF-β may have been due to the conversion of CD4+CD25- T cells to Foxp3+ 
iTreg cells.  To test this possibility, we stimulated FACS sorted CD4+CD25- T cells with 
plate-bound anti-CD3 plus either soluble or plate-bound anti-CD28 antibodies in the 
presence of TGF-β (including IL-2). Stimulation with plate-bound anti-CD3 and soluble 
anti-CD28 antibodies in the presence of TGF-β was used for inducible Treg cell polarizing 
conditions as previously reported (Fantini et al., 2007).   After 3 days of stimulation, 
expression of Foxp3 was examined by flow cytometry.  When stimulated by plate-bound 
anti-CD3 and soluble anti-CD28 antibodies in the presence of TGF-β (inducible Treg cells 
polarizing condition), a significant proportion of cells (37.3%) expressed Foxp3 (Fig. 21).  
However, only 5.3% of cells expanded with both the anti-CD3 and anti-CD28 antibodies 
being plate-bound expressed Foxp3.  The percentage of Foxp3+ T cells from plate-bound 
anti-CD28 antibody stimulated cells was comparable to those stimulated without TGF-β,  
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Fig. 21 Effect of TGF-β  on Foxp3 expression by CD4+CD25- T cells under PICA 
inducing stimuli.  CD4+CD25- T cells isolated from the spleen of C57BL/6 mice were 
stimulated with either plate-bound anti-CD3/anti-CD28 antibodies or plate-bound anti-
CD3 and soluble anti-CD28 antibodies in the presence of absence of TGF-β in media 
supplemented with IL-2. Cells were harvested at day 3 were stained for CD4 and Foxp3, 
and analyzed by flow cytometry.  
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Fig. 22 Effect of TGF-β  and IL-6 on PICA by CD4+CD25- T cells.   CD4+CD25- T 
cells isolated from the spleen of C57BL/6 mice were stimulated with either plate-bound 
anti-CD3/anti-CD28 antibodies or plate-bound anti-CD3 and soluble anti-CD28 
antibodies in the presence of absence of TGF-β, IL-6 in media supplemented with IL-2. 
(A) Cells were harvested at day 3 were re-stimulated with PMA and Ionomycin for 4 
hours in the presence of monensin and stained for IL-9 and IL-17 expression, then 
analyzed by flow cytometry. (B) Total number of IL-17+ cells and IL-9+ cells were 
determined based on the data obtained in (A).  
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suggesting inducible Treg induction did not occur with PICA inducing condition, 
plate-bound anti-CD3/ anti-CD28 antibody stimulation. Together, the data show that 
CD4+CD25- T cells treated with TGF-β become resistant to PICA not because CD4+CD25- 
T cells differentiated into inducible Treg cells.  
 
TGF-β promotes differentiation of Th9 cells under PICA-inducing condition 
       TGF-β is not only involved in iTreg cell differentiation but also for other helper T cell 
subset differentiations, such as Th9 or Th17 (Soroosh and Doherty, 2009; Yang et al., 
2010).  Since TGF-β rescued CD4+CD25- T cells from PICA without inducing Foxp3+ 
Tregs, we then determined whether cells survived PICA in the presence of TGF-β 
differentiated into other effector T cell subsets.   To address this question, we stimulated 
purified CD4+CD25- T cells with plate-bound anti-CD3 plus either soluble or plate-bound 
anti-CD28 antibodies in the presence or absence of TGF-β.  After 3 days of stimulation, 
cells expressing IL-9 or IL-17 were assessed by intracellular cytokine staining. CD4+CD25- 
T cells stimulated by plate-bound anti-CD3 plus anti-CD28 without TGF-β did not express 
IL-9, but a significant portion of the cells stimulated by the same manner in the presence of 
TGF-β expressed IL-9 (14%) (Fig. 22A).   The actual number of cells producing IL-9 also 
increased significantly with TGF-β (Fig. 22B), showing that TGF-β induced differentiation 
of a group of CD4+CD25- T cells into Th9 cells under PICA-inducing conditions. In 
contrast, CD4+CD25- T cells stimulated by plate-bound anti-CD3 plus soluble anti-CD28 
antibodies did not express IL-9 either with or without TGF-β.  No increase in Th17 cells 
was observed under either of these conditions (Fig. 22B).  These data suggest that PICA  
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Fig. 23 Effect of TGF-β  and IL-4 on PICA by CD4+CD25- T cells.   CD4+CD25- T 
cells isolated from the spleen of C57BL/6 mice were stimulated with either plate-bound 
anti-CD3/anti-CD28 antibodies or plate-bound anti-CD3 and soluble anti-CD28 
antibodies in the presence of absence of TGF-β, anti-IL-4 antibody in media 
supplemented with IL-2. (A) Cells harvested at day 3 were re-stimulated with PMA and 
Ionomycin for 4 hours in the presence of monensin and stained for IL-9 and IL-17 
expression, then analyzed by flow cytometry. (B) Culture supernatant was collected at 
day 3. IL-4 production was determined by ELISA.  ** p< 0.01  
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inducing conditions, stimulation with plate-bound anti-CD3/anti-CD28 antibody, 
promotes differentiation of CD4+CD25- T cells to Th9 subset. 
        Dardalhon et al. reported that Th9 is induced in an IL-4 dependent manner (Dardalhon 
et al., 2008). We then determined if Th9 cells were induced in an IL-4 dependent manner 
under plate-bound anti-CD3/anti-CD28 antibody stimulation. To address this question, we 
cultured electronically sorted CD4+CD25- T cells stimulated with plate-bound anti-CD3 
antibody plus either plate-bound anti-CD28 or soluble anti-CD28 antibodies in the presence 
or absence of anti-IL-4  (2C11 hybridoma culture supernatant). After 3 days of culture, we 
assessed IL-9 producing cells by cytokine staining. Indeed, addition of anti-IL-4 antibody 
abrogated induction of Th9 cells by TGF-β and plate-bound anti-CD3/anti-CD28 
antibodies (Fig. 23).  Whereas IL-4 producing cells were not detectable by cytokine 
staining after three days of stimulation (data not shown), culture supernatants from cells 
stimulated with plate-bound anti-CD3/anti-CD28 antibodies contained a clearly detectable 
level of IL-4 either in the presence or absence of TGF-β (Fig. 23B). TGF-β abrogated IL-4 
production in cells stimulated with plate-bound anti-CD3 and soluble anti-CD28 while no 
decrease of IL-4 was observed for cells stimulated with plate-bound anti-CD3/anti-CD28 
antibodies (Fig. 23B). In contrast to IL-4, the level of IFN-γ in the cytoplasm and culture 
supernatants from cells stimulated by plate-bound anti-CD3/antiCD28 antibody was 
moderately higher than that of cells stimulated by plate-bound anti-CD3 and soluble anti- 
CD28 antibodies (Fig. 24).  The data suggest that T cells stimulated with plate-bound anit-
CD3/anti-CD28 antibodies resist suppression of IL-4 production by TGF-β and 
differentiate into Th9 in part due to the presence of autocrine IL-4. 
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Fig.  24 Effect of TGF-β  and IL-6 on PICA by CD4+CD25- T cells.  CD4+CD25- T 
cells isolated from the spleen of C57BL/6 mice were stimulated with either plate-bound 
anti-CD3/anti-CD28 antibodies or plate-bound anti-CD3 and soluble anti-CD28 
antibodies in the presence of absence of TGF-β, IL-6 in media supplemented with IL-2. 
(A) Cells harvested at day 3 were re-stimulated with PMA and ionomycin for 4 hours in 
the presence of monensin and stained for IFN-γ expression, then analyzed by flow 
cytometry. Total number of IFN-γ+ cells was determined based on the data obtained in 
flow cytometry analysis.  (B) Culture supernatant was collected at day 3. IFN-γ 
production was determined by ELISA. ** p< 0.01, * p< 0.05 
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Fig. 25 Effect of TGF-β  and IL-6 on PICA by CD4+CD25- T cells.  CD4+CD25- T cells 
isolated from the spleen of C57BL/6 mice were stimulated with either plate-bound anti-
CD3/anti-CD28 antibodies or plate-bound anti-CD3 and soluble anti-CD28 antibodies in 
the presence of absence of TGF-β, IL-6 in media supplemented with IL-2. Culture 
supernatant was collected at day 3. IFN-γ production was determined by ELISA. ** p< 
0.01 
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         IL-6 plays a critical role in regulating the balance between Th17 and Treg cells 
and induces Th17 along with TGF-β (Kimura and Kishimoto, 2010).  Since IL-6 is mainly 
produced by non-T cell populations such as antigen presenting cells or non-hematopoietic 
cells including keratinocytes and fibroblasts, we next tested if exogenous IL-6 plus TGF-β 
changes the fate of CD4+CD25- T cells under PICA-inducing conditions.  When 
CD4+CD25- T cells were stimulated in the presence of TGF-β and IL-6, the frequency of IL-
17+ cells showed a modest increase over the TGF-β only control groups (Fig. 22A).  The 
increase was higher for plate-bound anti-CD28 antibody stimulation than soluble anti-
CD28 stimulation (3.7% over 1.4%).  In addition, we observed a substantial increase in the 
amount of IL-17 detected in the culture supernatant for cells stimulated with plate-bound 
anti-CD28 antibody than with soluble anti-CD28 controls (Fig. 25).  This was not merely 
due to an increase in total live cell numbers in the presence of exogenous IL-6 (Fig. 22B).  
Rather, there was a marked increase in the cell number of IL-17+ cells, suggesting that 
plate-bound anti-CD3/anti-CD28 antibody stimulation promotes differentiation and/or 
expansion of Th17 cells.    
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CHAPTER FOUR 
DISCUSSION 
 
Introduction 
       CD4+CD25+ Treg cells comprise about 5-10% of CD4+ T cells in the periphery of 
mice and humans. Since Tregs suppress immune responses, the balance between Treg 
cells and effector T cells is critical in determining an immunogenic or tolerogenic 
environment in the body. During an infection, the immunogenic environment is needed to 
fight against pathogens, thus effector CD4+ T cells undergo clonal expansion by 
recognizing their cognate antigen via TCR and orchestrate other immune cells by 
producing a variety of cytokines. On the other hand, excess immunity leads to tissue 
damage and can cause autoimmune disorders. Therefore, expanded effector T cells 
undergo apoptosis following an immune response. This event is known as activation 
induced cell death (AICD) (Shi et al., 1989). However, it has not been addressed how 
CD4+CD25+ Treg cells respond to antigen stimulation compared to effector CD4+ T cells. 
Since effector T cells are needed for an immune response and Treg cells are required for 
maintaining peripheral tolerance, the responses to antigen stimulation in Treg cells might 
be different from other CD4+ T cells. 
        Our laboratory recently discovered the phenomenon that CD4+CD25- T cells 
undergo apoptosis when stimulated with plate-bound anti-CD3/anti-CD28 antibodies 
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over 4 days in the presence of IL-2, while Treg cells survive and expand (Singh et al., 
2010). Classical AICD occurs in a p53 independent manner, however we found that the 
cell death due to plate-bound anti-CD3/CD28 antibody stimulation is mediated by a novel 
form of the apoptosis pathway (p53-induced and CD28-dependent apoptosis: PICA) and 
is distinct from classical AICD.  Other groups have reported that p53 deficient mice 
develop exacerbated experimental autoimmune arthritis, experimental autoimmune 
encephalomyelitis and streptzotocin-induced diabetes even though p53 deficient T cells 
are sensitive to AICD (Okuda et al., 2003; Simelyte et al., 2005; Zheng et al., 2005). 
These observations led us to hypothesize that PICA is important to control the balance of 
Treg cells versus non-Treg cells in the periphery. Understanding the differential survival 
mechanisms between Treg cells and non-Treg cells against PICA might give us a better 
understanding of peripheral tolerance and help us to identify therapeutic targets to treat 
immune dysregulation such as autoimmune diseases, GVHD, and cancer. 
        In this study, we focused on two different aspects that mediate differential survival 
mechanisms of Treg cells compared to non-Treg cells under PICA inducing condition, 
plate-bound anti-CD3/anti-CD28 antibody stimulation in vitro. First, from a TCR 
proximal signaling study, we found that the Ras activator, Ras guanyl nucleotide 
releasing proteins (RasGRP1) expression was substantially reduced in Treg cells 
compared to effector T cells (non-Treg cells) and its downstream Ras-Erk pathway was 
significantly impaired. Further, non-Treg cells which lack RasGRP1 expression were 
resistant to PICA and they expanded under PICA inducing stimuli. Second, we found that 
TGF-β signaling rendered CD4+CD25- T cells resistant to PICA and was required for 
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survival and expansion by CD4+CD25+ Treg cells when stimulated with plate-bound 
anti-CD3/anti-CD28 antibodies. These data suggest that both TGF-β and RasGRP1 
signaling play crucial roles in mediating PICA thus balancing the proportion of Treg cell 
and non-Treg cell subsets.  
 
RasGRP1 expression in CD4+ T cells and PICA 
      Our data demonstrates that RasGRP1 expression is substantially reduced in Treg cells 
compared to non-Treg cells (CD4+CD25- T cells) after TCR activation. To determine if 
reduced RasGRP1 expression in Treg cells is one of the survival mechanisms under 
PICA inducing conditions, we used RasGRP1 deficient non-Treg cells (CD4+CD25- T 
cells). Our data show that RasGRP1 deficient non-Treg cells are resistant to PICA under 
plate-bound anti-CD3/CD28 antibody stimulation, suggesting that RasGRP1 signaling is 
required for inducing PICA in non-Treg cells.  
        RasGRPs are activators for Ras by converting the Ras-GDP bound form to the 
active Ras-GTP form (Dower et al., 2000). TCR signaling leads to activation of 
Phospholipase C γ (PLCγ) which produces diacylglycerol (DAG). The DAG recruits 
RasGRP1 to the plasma membrane allowing RasGRP1 to interact with Ras thus 
activating Ras-Erk signaling. T cells dominantly express RasGRP1 among RasGRP 
family members (RasGRP1, 2, 3, 4) and RasGRP1 plays a critical role in T cell immunity 
have been demonstrated using RasGRP1 deficient mice or lag mice which have mutations 
in the rasgrp1 gene.  Layer et al. showed that lag mice develop lymphoadenopathy at 3 to 
4 month old (Layer et al., 2003). These mice possess enlarged spleens containing a larger 
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number of CD4+ T cells compared to wild type littermate controls and developed an 
autoimmune disorder which is depicted by high levels of antinuclear antibodies in the 
serum. Transferring the T cells isolated from lag mice (RasGRP1 mutant mice) into T 
and B cell deficient mice (Rag knockout mice) causes the host to develop an autoimmune 
disorder, suggesting RasGRP1 expression in CD4+ T cells is required for maintaining 
immune homeostasis.  Priatel et al. reported that adoptive transfer of CD4+ T cells 
isolated from RasGRP1 knockout mice into congenic host mice also develop exacerbated 
autoimmune disorder phenotype compared to wild type CD4+ T cells transferred into the 
host (Priatel et al., 2007). These data also support the idea that RasGRP1 expression in 
CD4+ T cells is required for maintaining immune homeostasis. RasGRP1 is known to be 
required for T cell development in the thymus (Dower et al., 2000). Positive selection is 
impaired in RasGRP1 deficient mice but negative selection is normal in these mice, 
suggesting central tolerance is kept intact. Why do RasGRP1 deficient mice develop an 
autoimmune disorder? One of the mechanisms might be dysregulation of peripheral 
tolerance in RasGRP1 deficient mice. Our data demonstrate that RasGRP1 expression is 
substantially upregulated in non-Treg cells in response to TCR stimulation. Further, 
CD4+CD25- T cells isolated from RasGRP1 deficient mice become resistant to PICA 
under stimulation with plate-bound anti-CD3/anti-CD28 antibodies over 4 days while 
wild type non-Tregs undergo massive apoptosis. Altogether, we propose the model that 
effector CD4+ T cells which lack RasGRP1 expression cannot undergo apoptosis and 
survive, hence the increased ratio of effector CD4+ T cells (non-Treg cells) against Treg 
cells break a tolerance thus causing an autoimmune syndrome. 
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      Recently, Yasuda et al. reported systemic lupus erythematosus (SLE) patients 
express lower levels of RasGRP1 compared to healthy donors (Yasuda et al., 2007). They 
also showed that SLE patients had a higher frequency of alternating splicing of rasgrp1 
which produces a dysfunctional protein. Wen et al. also reported that RasGRP1 
expression is lower in SLE patients compared to healthy donors (Pan et al., 2010). Their 
data suggest that microRNA-21 is highly expressed in SLE patient and further 
microRNA-21 directly the downregulates RasGRP1 expression. These data also support 
our model that PICA is balancing Treg cells and non-Treg cells in an RasGRP1 
dependent manner. 
       Our previous report shows that RasGRP1 expression is downregulated in Treg cells 
compared to non-Treg cells. Since lowered RasGRP1 expression seems to induce 
dysregulation of effector T cells, reduced expression of RasGRP1 in Treg cells may be 
critical to maintain immune homeostasis. 
       We have previously shown that PICA is induced in a Bim and Fas/Fas ligand 
interaction dependent manner (Singh et al., 2010). Our data demonstrate that the 
proapoptotic protein, Bim, is substantially reduced in RasGRP1 deficient non-Treg cells 
(CD4+CD25- T cells) under plate-bound anti-CD3/anti-CD28 antibody stimulation 
compared to littermate control. This suggests that RasGRP1 signaling mediates 
upregulation of Bim under PICA inducing conditions. Further, reduced expression of 
Bim in Treg cells under plate-bound anti-CD3/anti-CD28 antibody stimulation might also 
be due to downregulated RasGRP1 expression. Recently, Stang et al. reported that 
activating RasGRP1 signaling by the DAG analogue, breostatin, leads to apoptotic cell 
  
96 
death in the Tredo non-Hodgkin’s B cell lymphoma line (Stang et al., 2009). They also 
demonstrated that apoptotic cell death is mediated by phosphorylation of the proapoptotic 
protein, Bim, through the activation of the RasGRP-Ras-Erk pathway. We have not 
examined if PICA is induced by ERK activity. We can address this question by treating 
non-Treg cells (CD4+CD25- T cells) with a Mek inhibitor (PD98059 or UO1). If PICA is 
induced in an Erk acrivity dependent manner, we would expect to observe that non-Treg 
cells treated with the Mek inhibitor avoid apoptosis and survive under plate-bound anti-
CD3/CD28 antibody stimulation. 
      We have demonstrated that non-Treg cells which lack RasGRP1 expression are 
resistant to PICA. Hence, it is expected that the downregulation of RasGPR1 expression 
in Treg cells is important for cell survival under PICA inducing stimuli. However, we 
haven’t addressed if the downregulation in Treg cells is required for Treg cell survival 
under plate-bound anti-CD3/anti-CD28 antibody stimulation. It would be interesting to 
address if overexpression of RasGRP1 renders Treg cells sensitive to PICA. Due to 
technical difficulties with the use of a retrovirus or lentivirus transduction system on 
murine Treg cells to overexpress RasGRP1, we were not successful in addressing this 
question. In future studies, an alternative approach such as co-overexpressig Foxp3 and 
RasGRP1 in non-Treg cells can be tested. If downregulation of RasGRP1 expression is 
important for Treg survival under plate-bound anti-CD3/anti-CD28 antibody stimulation, 
we would expect to see CD4+ T cells co-overexpressed Foxp3 and RasGRP1 undergo 
apoptosis under PICA inducing stimuli.   
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Regulation of RasGRP1 expression in T cells 
       As described above, previous reports show that RasGRP1 deficient mice exhibit 
substantially reduced single positive T cells in the thymus. Since they have normal 
numbers of double positive T cells, RasGRP1 is required for positive selection but not for 
negative selection. RasGRP1 is expressed in all stages of thymocyte development as well 
as peripheral T cells. Han et al. showed that EL4 lymphoma cells derived from murine 
thymoma also expresses RasGRP1 and EL4 cells downregulate RasGRP1 expression in 
response to PMA stimulation (Han et al., 2007). PMA, a DAG analogue, renders 
RasGRP1 to translocate into the plasma membrane by directly binding to C1 thus 
allowing RasGRP1 to associate with Ras. Since DAG is produced upon TCR stimulation, 
this data led us to think that RasGRP1 expression might be downregulated in response to 
TCR stimulation. Contrary to what was expected from previous study, our data 
demonstrate that RasGRP1 expression is substantially increased after 7 days of ex vivo 
stimulation in non-Treg cells (CD4+CD25- T cells). Interestingly, Treg cells continuously 
expressed basal levels of RasGRP1. Presently, it is not known if upregulation of 
RasGRP1 expression in non-Treg cells (CD4+CD25- T cells) has any specific roles in 
effector CD4+ T cells. Ebinu et al. reported overexpression of RasGRP1 in human Jurkat 
T cell lines leads to a higher production of IL-2 (Ebinu et al., 2000). Perhaps, this 
upregulation of RasGRP1 expression might be required for non-Treg cells to possess 
effector functions such as cytokine production. Future study is needed to address this 
question.  On the other hand, Treg cells retained basal levels of RasGRP1 expression 
after ex vivo stimulation for 7 days. We found that the difference of RasGRP1 expression 
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in ex vivo expanded Treg cells and non-Treg cells is controlled at the transcriptional 
level. The rasgrp1 mRNA level was about 15 fold lower in expanded Treg cells 
compared to non-Treg cells. 
      Foxp3 is a transcription factor which belongs to the forkhead family and is 
specifically expressed in Treg cells. Since Foxp3 positively or negatively control many 
genes related to Treg cell functions, we hypothesized that Foxp3 controls rasgrp1 
transcription.  To address this question, we performed a ChIP assay on expanded Treg 
cells using anti-Foxp3 antibody. We found 4 sites that a contain forkhead consensus 
sequence up to 4kb upstream of the rasgrp1 transcription starting site. Primers designed 
to detect two of the sites amplified a strong band from the Foxp3 antibody precipitated 
sample but not from the isotype IgG control antibody precipitated sample, suggesting that 
Foxp3 indeed binds to the rasgrp1 gene transcription regulation region. Recently, Marson 
et al. performed that ChIp assay combined with gene chip microarray using murine T cell 
hypridoma that overexpressed Foxp3. They reported that Foxp3 controls about 1,100 
genes including well known Foxp3 target genes such as IL-2 and CTLA4 (Marson et al., 
2007). Zheng et al. also performed a similar approach as Mason et al. and reported that 
Foxp3 controls about 1,200 genes using CD4+CD25+ Treg cells isolated form C57BL/6 
mice (Zheng et al., 2007). Neither of them identified the rasgrp1 gene as a Foxp3 target. 
Our study is the first to report Foxp3 targets the rasgrp1 gene. There are a few 
possibilities why the rasgrp1 gene was not identified as a Foxp3 target. A microarray 
based approach might select a target gene with stringent conditions, thus rasgrp1 was not 
picked up. Another possibility is that Foxp3 might bind to the rasgrp1 gene only after 
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cells are activated. Since we used ex vivo expanded Treg cells stimulated for 7 days 
with plate-bound anti-CD3/anti-CD28 antibodies for the ChIP assay, Treg cells were in 
an activated state. We also observed that freshly isolated Treg cells and non-Treg cells 
expressed comparable level of RasGRP1. This also supports the idea that Foxp3 binds to 
the rasgrp1 gene after TCR activation. Future studies are needed to determine if Foxp3 
binds to rasgrp1 before or after TCR stimulation. 
        We have demonstrated that Foxp3 targets the rasgrp1 gene, but we have not 
addressed if Foxp3 binding leads to the downregulation of rasgrp1 transcription in Treg 
cells. One mechanism by which Foxp3 negatively regulates gene expression is 
competition of the binding site with the transcription factor, nuclear factor of activated T 
cells (NFAT) (Schubert et al., 2001). NFAT mediates immune functions such as cytokine 
production and the activity of NFAT is regulated by calcium signaling. We found that the 
NFAT binding consensus sequence exists adjacent to one of the potential Foxp3 binding 
sites, 3kb upstream of the rasgrp1 transcription starting site. In future studies, it will be 
interesting to address if downregulation of rasgrp1 transcription is due to Foxp3 
competing with NFAT for its binding site. This question can be examined by performing 
a ChIP assay using NFAT antibody. We can compare NFAT binding to the rasgrp1 gene 
in Foxp3 overexpressed CD4+CD25- T cells using a retroviral transduction system. We 
can also test if Foxp3 negatively regulates RasGRP1 by transiently overexpressing Foxp3 
in non-Treg cells using retrovirus transduction and assess rasgrp1 transcription levels by 
real time PCR. If Foxp3 downregulates RasGRP1 expression, we would expect to see 
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decreased rasgrp1 gene expression in Foxp3 transduced non-Treg cells compared to 
control cells. 
       A recent report shows that microRNA-21 directly targets RasGRP1 expression and 
downregulates expression levels (Pan et al., 2010). Other groups have reported that 
microRNA-21 is highly expressed in Treg cells compared to non-Treg cells (Rouas et al., 
2009). Taken together, there might be a RasGRP1 downregulation mechanism by 
microRNA-21 along with transcriptional regulation of rasgrp1 by Foxp3. Understanding 
the role of microRNA-21 in Treg cells might give us another regulation mechanism of 
RasGRP1 in Treg cells. In the future, it would be interesting to examine the role of 
microRNA-21 under PICA inducing condition. 
 
TGF-β signaling decides the fate of non-Treg cells and Treg cells under PICA inducing 
conditions 
       Our data demonstrate that TGF-β signaling is required for Treg cell survival under 
plate-bound anti-CD3/anti-CD28 antibody stimulation. Nakamura et al. reported that 
TGF-β production in response to TCR stimulation was higher in Treg cells compared to 
non-Treg cells by measuring total TGF-β from culture supernatants (Nakamura et al., 
2001). However, this assay does not tell how much active TGF-β, which can be 
associated with TGF-β receptor is present in culture supernatant of Treg cells or non-
Treg cells. Our data show that Treg cells undergo apoptosis under plate-bound anti-
CD3/antiCD28 antibody stimulation when TGF-β signaling is blocked by a chemical 
inhibitor (SB431542) or an anti-TGF-β neutralizing antibody.  In contrast, non-Treg cells 
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became resistant to PICA in the presence of exogenous active TGF-β. Taken together, 
it is expected that Treg cells might possess specific mechanisms to release the active form 
of TGF-β. To convert latent TGF-β to the active form, latent associated protein (LAP) 
needs to be cleaved from TGF-β by TGF-β activators such as integrins or 
thrombospondin-1 (TSP-1) (Masli et al., 2006). Currently, it is not understood if Treg 
cells express these molecules. It has been demonstrated that Treg cells but not other T 
cells express a membrane bound form of TGF-β. There might be specific mechanisms to 
convert latent TGF-β into the active form of the membrane bound TGF-β, thus Tregs but 
not non-Tregs are able to survive under PICA inducing conditions. Recently, Oida et al. 
reported that murine CD4+CD25- T cells also express the membrane bound of TGF-β 
without inducing Foxp3+ inducible Treg cells (iTreg) when cells were stimulated in the 
presence of exogenous TGF-β (Oida and Weiner, 2010). This observation supports the 
idea that membrane bound TGF-β might be important for Treg and non-Treg cell survival 
under PICA inducing conditions.  In future studies, we can address the production of the 
active-form of TGF-β by Treg cells or non-Treg cells under plate-bound anti-CD3/anti-
CD28 antibody stimulation. Further, it would be interesting to determine the role of 
membrane bound TGF-β in Treg cell survival under PICA inducing conditions. To 
address this question, we can knockdown GARP which anchors TGF-β on the cell 
surface. If membrane bound TGF-β has a specific role for Treg cell survival under plate-
bound antibody stimulation, GARP knockdowned Treg cells might become sensitive to 
PICA.  
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      Our data show that TGF-β signaling reduces expression of Bim. Recent reports 
showed that TGF-β regulates expression of Bim in non-lymphoid cells and mitogen- and 
stress-activated protein kinase-1 (MSK-1) plays a critical role in the anti-apoptotic 
functions of TGF-β (Hoshino et al., 2011; van der Heide et al., 2011). Currently, it is not 
known if MSK plays any role in T cell activation or death. In the future, it will be 
interesting to determine by which mechanisms TGF-β signaling downregulates Bim 
expression. Complex and intricate regulation of Bim by TGF-β potentially reflects what 
has been reported on the role of microRNA-25 (Petrocca et al., 2008). In CD4+CD25- and 
CD4+CD25+ T cells, Bim protein levels are negatively regulated by TGF-β. Notably, 
recent reports show that microRNA-25, which regulates Bim protein synthesis and 
promotes anti-apoptotic responses, was much reduced in Treg cells from patients with 
multiple sclerosis (De Santis et al., 2010; Li et al., 2009). Loss of this microRNA could 
lead to an increase in Bim protein expression by Treg cells and their death, hence less 
effective maintenance of self-tolerance. In the future, we can determine the role of 
microRNA-25 in Bim expression in Treg cells under PICA inducing conditions. 
      Recently, Ouyang demonstrated that TGF-β promotes nTreg cells cell survival during 
negative selection, where Bim plays a critical role (Ouyang et al., 2010). Though thymic 
selection does not require p53, the data suggest that TGF-β signaling can be anti-
apoptotic under certain conditions in connection to Bim expression. Though PICA is an 
ex vivo event established by use of anti-receptor antibodies, our previous work shows that 
PICA can be induced by extended stimulation from allogenic dendritic cells in vitro 
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(Singh et al., 2010). Therefore, it will be interesting to see if TGF-β rescues effector 
T cells from PICA in vivo.  
 
PICA inducing conditions skews differentiation of CD4+ T cells 
      We have demonstrated that TGF-β signaling promotes the differentiation of 
CD4+CD25- T cells that receive PICA inducing stimuli. Our data show that non-Tregs 
(CD4+CD25- T cells) become resistant to PICA in the presence of exogenous TGF-β 
under plate-bound anti-CD3/anti-CD28 antibody stimulation. Since TGF-β is known to 
promote inducible Treg cell differentiation, we expected that Foxp3+ T cells were 
induced under PICA inducing stimuli, thus they became resistant to PICA. However, this 
phenomenon is not due to induction of Foxp3+ inducible Treg cells. Our data suggest that 
non-Treg cells preferentially differentiated into Th9 (IL-9 producing cells) in an IL-4 
dependent manner instead of becoming iTreg cells in the presence of TGF-β under PICA 
inducing stimuli. Further, IL-17 production is also substantially increased under PICA 
inducing stimuli compared to plate-bound anti-CD3/ soluble anti-CD28 antibody 
stimulation. Currently, the molecular mechanisms that underlie this phenomenon are 
unknown. TGF-β may be simply providing a signal required for survival of T cells and 
IL-4 provides differentiation signaling for Th9. Similary, TGF-β might allow T cells to 
survive PICA so that exogenous IL-6 can induce differentiation of surviving cells into 
Th17 cells. Alternatively, TGF-β could also provide the signaling required for 
initiation/establishment of differentiation. In either case, the plasticity of CD4+ T cell  
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Fig. 26 Schematic model of CD4+ T cells under PICA inducing stimuli. Conventional 
CD4+ T cells undergo PICA when stimulated with plate-bound anti-CD3/CD28 
antibodies, whereas nTreg cells expand robustly under same conditions. TGF-β signaling 
and reduced RasGRP1 expression mediate survival of nTreg cells under PICA inducing 
stimuli. Conversely, when an active form of exogenous TGF-β is present, non-Treg cells 
become resistant to PICA and undergo robust expansion instead of apoptosis, with 
reduction of the proapoptotic protein Bim. Substantial fraction of PICA-resistant T cells 
expressed IL-9. Moreover, the presence of IL-6 along with TGF-β led to the generation 
of Th17. 
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differentiation provided by TGF-β and PICA stimulation might play significant roles 
in determining the outcomes in vivo (Fig. 26). 
       Accumulated evidence suggests that TGF-β promotes iTreg cell differentiation with 
antigen stimulation. However, we have discovered that PICA inducing stimuli does not 
induce iTreg cell differentiation even in the presence of TGF-β. Conversely, non-Treg 
cells differentiated into Th9 cells instead of becoming iTreg cells under PICA inducing 
stimuli when TGF-β was present. Further more, in Th17 polarizing conditions, PICA 
inducing stimuli induced more IL-17 producing cells compared to soluble anti-CD28 
stimulation. Since Th9 and Th17 cells mediate effector immune responses by producing 
IL-9 and IL-17, these data indicate that the condition of PICA inducing stimuli might be 
able to shift physiological conditions from a tolerogenic to an immunogenic environment 
even in the presence of TGF-β, which possesses immune suppressive effects. In our 
study, we have used plate-bound anti-CD3/anti-CD28 antibody stimulation as PICA 
inducing stimuli compared to plate-bound anti-CD3 plus soluble anti-CD28 antibody 
stimulation. At present, it is not clear how the difference caused by plate-bound anti-
CD28 antibody compared to soluble anti-CD28 antibody leads to a different outcome on 
the survival of non-Treg cells in the presence of TGF-β. It would be interesting to address 
the mechanism by which plate-bound anti-CD28 antibody stimulation skews the 
difference of CD4+ T cells compared to soluble anti-CD28 antibody stimulation. Since the 
difference of these stimulations is only the type of anti-CD28 antibody stimulation, we 
propose to determine the downstream CD28 signaling pathway by co-
immunoprecipitating CD28 associating molecules using anti-CD28 antibody under plate-
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bound anti-CD28 stimulation. We expect that CD28 interacting protein such as AKT 
might be differentially regulated between plate-bound anti-CD28 and soluble anti-CD28 
antibody stimulated cells. Although it still remains unclear and needs to be addressed, the 
molecular mechanisms behind skewing CD4+ T cell differentiation under PICA inducing 
stimuli has potential applications in clinical settings as an immunotherapy tool for 
treating disease or immune disorders. 
       We propose the potential applications of PICA inducing stimuli as cancer vaccines 
for the following reasons. First, PICA inducing stimuli blocks iTreg cell differentiation in 
the presence of TGF-β. TGF-β plays an important role in tumor development. Many 
types of tumor cells produce large amounts of TGF-β in the tumor microenvironment and 
TGF-β production leads to conversion of CD4+ T cells into iTreg cells. For example, Lu 
et al. demonstrated that gastric cancer cells directly convert CD4+ T cells into iTreg cells 
in a TGF-β dependent manner (Lu et al., 2011). Liu et al. demonstrated that non-Treg 
cells converted into iTreg cells at the tumor site in a TGF-β dependent manner using a 
mouse model (Liu et al., 2007). This is known to be one of the tumor evasion 
mechanisms to escape immune surveillance (Curiel, 2007; Nishikawa and Sakaguchi, 
2010). If we can mimic PICA inducing stimuli at the tumor site, we would expect to see 
the blockade of iTreg cell induction at the tumor site thus gaining a more efficient 
immune response to fight against cancer.  
       Secondly, PICA inducing stimuli made non-Treg to differentiate into Th9 cells in the 
presence of TGF-β. Further, they differentiated into Th17 and produced large amounts of 
IL-17 when TGF-β and IL-6 were present. If we can match PICA inducing stimuli at the 
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tumor sites, Th17 and Th9 cells might trigger an effective immune response by 
producing IL-17 and IL-9. 
       Therefore, we would like to further address how we can duplicate PICA inducing 
stimuli at the tumor site. Since CD28 signaling is thought to play a key role, we will 
examine modulation of CD28 signaling for T cells at the tumor site by administration of 
anti-CD28 antibody or overexpression of B7, which is the ligand for CD28 on APCs. 
 
Conclusion remarks 
       My work provides insight into how nTreg cells survive under antigen stimulation 
while conventional CD4+ T cells undergo apoptosis. My work suggests that reduced 
RasGRP1 expression and TGF-β signaling mediate the survival of nTreg cells under 
PICA inducing stimuli. These altered signals in Treg cells are likely regulating the 
balance of nTreg cells and conventional T cells during immune response thus maintaining 
immune homeostasis. These could be new therapeutic targets to treat immune 
dysregulations. 
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